E-COPIES OF SANCTIONED LETTERS FOR THE GRANT RECEIVED FROM NON-GOVERNMENT AGENCIES

2017-2018

SWAMI VIVEKANAND SUBHARTI UNIVERSITY

MEERUT



ગુજરાત ગુજરાત GUJARAT AZ 517122

નંબર: ૨૪૨૫૫૫ રૂ. ૧૦૦

તારીખ: 23 માહે ૯ સને ૨૦૧૬

નામ:

સરનામું: 23 SEP 2016

કૈલેષકુમાર વાસુદેવભાઈ ત્રિવેદી

લા. નં.:- ઓસ. બી.- ૬૩/૧૯૮૬

અમદાવાદ-સીટી સીવીલ કોર્ટનુ સણંદી

લેનાર ની સહીx:.....

Cliantha Research Limited
Opp. Pushparaj Towers,
Nr. Judges Bunglows,
Bodakdev, Ahmedabad-380054.
Ph. : +91-79-26853088-92
Fax : +91-79-26853093

CLINICAL TRIAL AGREEMENT

PROTOCOL Number: CP/04/12

This Clinical Trial Agreement (the **"Agreement"**) is effective on the date 22 Aug 16 fully executed by the parties (the **"Effective Date"**) and entered into by and between

CLIANTHA RESEARCH LIMITED, a part of Cliantha Group, a company incorporated under the Companies Act, 1956 having its Registered Office at Opp. Pushparaj Towers, Nr. Judges Bungalows, Bodakdev, Ahmedabad – 380 054, India (hereinafter referred to as **"CRO"** which expression, unless repugnant to the context or meaning thereof shall mean and include its affiliates, employees, assignees, subsidiaries, nominees, agents and successors-in-interest)

AND

DR. SHASHI PRATEEK whose principal place of business is **SUBHARTI MEDICAL COLLEGE,** Subharti Puram, NH-58, Delhi Haridwar Bypass Road, Meerut, Uttar Pradesh 250005 India hereinafter referred to as the **"Principal Investigator"** which expression, unless repugnant to the subject or context therein, shall mean and include his legal heirs, administrators, executors and assigns)

AND

Principal Dr. A.K Asthana on behalf of Subharti Medical College and Hospital an institute registered under the law of India having its registered office at Subharti Puram, NH-58, Delhi Haridwar Bypass Road, Meerut, Uttar Pradesh 250005 India (hereinafter referred to as the **"Institution"** which expression, unless repugnant to the subject or context therein, shall mean and include its authorized representative(s), administrators, executors, assigns & successors-in-interest).

CRO, Institution and Principal Investigator are referred to herein individually as a "Party" and collectively as "Parties".

Whereas, Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013. (hereinafter referred to as the **"Sponsor"**) through its Agent **CRO** desires the Institution to study the Comparative clinical study of Ulipristal acetate and the Institution is willing to perform a clinical study of the Study Drug (defined herein below); and

WHEREAS, the Study (defined below) is of mutual interest and benefit to the Sponsor, CRO, Institution and Principal Investigator and will further the investigational and research objectives of the Institution and Principal Investigator;

WHEREAS, the Principal Investigator and the Institution have the **qualified personnel and the facilities** equipped according to Good Clinical Practices (GCP) to undertake the Study (defined herein below);

NOW, THEREFORE, in consideration of the promises and mutual covenants herein contained, the Parties agree as follows:

1. THE STUDY AND THE PROTOCOL

The study of Ulipristal acetate (the **"Study Drug"**) shall be conducted, under the direction of the Principal Investigator, in the treatment of patients (**"Subjects"**) in accordance with this Agreement and the protocol identified as Protocol ID No. CP/04/12 and entitled "A randomized, open label, parallel-group, active-comparator controlled, multi-center study to evaluate the efficacy and safety of Ulipristal acetate (5 mg tablets), as compared with Leuprolide acetate (3.75 mg intramuscular injection) for 12 weeks, in the preoperative treatment of moderate to severe symptomatic uterine fibroids" a copy of which is attached hereto as Exhibit A (the **"Protocol"**), including any subsequent duly authorized amendments, and which is hereby incorporated by reference (the **"Study"**). The Study will be monitored on behalf of the Sponsor by the CRO.

Institution's obligation to conduct the Study is expressly conditioned upon the approval of the Protocol by an IEC/IRB that complies with the requirements of Drug Controller General of India and Schedule Y and applicable regulatory requirements. Sponsor, Principal Investigator and Institution shall cooperate in preparing and filing the Protocol, Informed Consent Form and other information with the reviewing IEC (Individual Ethics Committee) or IRB (Institutional Review Board).

2. THE STUDY SCHEDULE

A. **Study Initiation.** All contractual and regulatory documentation must be received by Sponsor and CRO before the initiation of the Study. The Principal Investigator and CRO shall initiate the Study at the earliest after receiving the applicable regulatory / IEC / IRB approvals.

B. **Enrollment.** Principal Investigator will enroll minimum 5 Subjects (as per the randomization schedule provided) and not more than 15 Subjects (as per the randomization schedule provided) (the **"Site Maximum"**) for the duration of enrollment. The Principal Investigator shall commence enrollment of the

Subjects once all the contractual and regulatory obligations have been met. Enrollment of, and payment for, each Subject over the Site Maximum shall require prior written consent of the Sponsor. Notwithstanding the foregoing, the Institution immediately shall cease enrolling the Subjects upon receipt of notice from the Sponsor, or the Sponsor's designee, that, in the sole determination of the Sponsor:

i. the Complete Study enrollment has been achieved; or

ii. the Sponsor has placed the Study on hold, for any reason; or

iii. the Study has been placed on hold by the DCGI or applicable regulatory agency for any reason.

C. **Study Documentation.** Case Report Forms (**"CRFs"**) must be satisfactorily completed within **3** (Three) days of each Subject visit. If any tests are to be performed after the Subject visit, CRF shall be completed within **Three (3) days** of receipt of test results for each Subject, provided, however, that with respect to the last Subject enrolled at the Site, CRF for such Subject must be completed within **three (3) days** of such Subject's last visit to the Site. The Principal Investigator shall ensure the accuracy, completeness, legibility and timeliness of the data reported to the Sponsor in the CRFs and in all required reports. Safety data (Serious Adverse Event Report Forms) will be faxed to Sponsor, DCGI and CRO within 24 hours of (i) the Subjects visit and (ii) receipt of the test results at, or from which, such event was reported, noted or recognized. Data Clarification Forms Queries (**"DCFs"**) must be completed and returned to Sponsor and CRO within **Three days** of its receipt.

D. **Subject Samples.** All biological samples collected from the Subjects shall be prepared and shipped in accordance with appropriate reference of the Protocol / Study requirements / Study manuals.

E. **Study Completion.** The Institution **shall make best efforts to complete** the enrollment of all the Subjects within the specified timeline given or informed by the Sponsor/ CRO. The Institution shall input all final CRF data and complete the final CRFs not later than five days after the last Subject visit.

3. PAYMENT

A. **BUDGET AND PAYMENT SCHEDULE**: CRO, on behalf of the Sponsor reimburse the Institution all direct and indirect costs incurred by the Institution in accordance with the Budget and Payment Schedule, attached hereto as Exhibit B and incorporated herein by reference (the **"Budget and Payment Schedule"**). CRO shall make payments to the investigator and Institution in accordance with the payment schedule set forth in Exhibit b and incorporated herein . Cheque(s) shall be made payable and sent to the:

Payee Name: SUBHARATI K. K. B. CHARITABLE TRUST
PAN: AADTS2638D

Payment shall be made within thirty (30) days after CRO has received invoice from the Principal Investigator. In addition, CRO shall reimburse directly the IEC / IRB for all costs associated with the Study.

B. **Payment of Costs Outside Budget and Payment Schedule.** Payment for any costs not specifically described in the Budget and Payment Schedule must be approved in advance in writing by the CRO's Project Manager.

C. **Payment Terms.** CRO shall have no obligation to make payments for any Subject who is not qualified to participate in the Protocol based on the inclusion and exclusion criteria described in the Protocol. Queries pertaining to a Subject's eligibility shall be addressed to and resolved by the Sponsor's Clinical and/or Medical Monitor identified in the Protocol prior to entry of any such Subject into the Study.

The foregoing notwithstanding:

Upon submission of such documentation as may be requested, to the extent not already paid by CRO, CRO will pay the actual cost of completed visits in accordance with the Budget and Payment Schedule for the Subjects who are dropped from the Study or withdraw from the Study; provided, however, such costs were incurred at a time when, in the good faith judgment of CRO, none of the Institution, its employees or agents, or the Principal Investigator knew or could have reasonably determined that such Subject was not or would not be an Eligible and Evaluable Subject. **"Eligible and Evaluable Subjects"** are defined as Subjects who have satisfied all the Protocol requirements, including compliance with dosing regimen and visit schedule, and are eligible to be included in the statistical analysis for the Study; and Institution and Principal Investigator agree that all payments made under this Section are made solely for the performance of activities relating to the Study and for no other purpose.

D. **Payment Recipient and Mailing Address.** All cheques shall be made payable to the entity / person mentioned in the Clause 3A.

The mailing address for checks shall be:

Address: **Dr H. L Bhalla, Project manager & investigator**
Department of Pharmacology
SUBHARTI MEDICAL COLLEGE,
Subharti Puram, NH-58, Delhi Haridwar Bypass Road, Meerut,
Uttar Pradesh 250005
Ph : 9761715236 , 9927971349

Attn: **Dr. Shashi Prateek**

PAYMENT DETAILS **Annexure IA**

Head	Cheque to be drawn in favor of	PAN
Full payment	SUBHARATI K. K. B. CHARITABLE TRUST	AADTS2638D

E. **Reimbursement.** Upon completion of the Study or earlier termination of this Agreement as provided herein, the Institution shall reimburse the CRO for any amounts that were paid by the CRO to the Institution which exceed the amounts to which the Principal Investigator was entitled for completed Subject visits under the Budget and Payment Schedule of this Agreement.

F. **Payments for Screen Failure:** Sponsor will pay only Rs. 1000/- (Rupees one thousand only) per Subject for screen failure. The maximum ratio for screen failure Subjects shall be 3:1 i.e. maximum one screen failure per three randomized Subjects.

4. OBLIGATIONS OF THE INSTITUTION AND THE PRINCIPAL INVESTIGATOR

A. **IEC / IRB Approval.** The Principal Investigator shall be responsible, with the cooperation of the Institution and Sponsor, for obtaining approval from the IEC / IRB of the Protocol and the Subject's Informed Consent Form. The Principal Investigator shall provide the Sponsor or Sponsor's designee with written confirmation of the IEC / IRB's approval prior to the **screening** of Subjects. If the IEC / IRB withdraw approval of the Study, at any time, the Principal Investigator shall be immediately notified by the Sponsor or CRO, providing a written explanation of the circumstances leading to such withdrawal of approval, and **the Principal Investigator shall cease the treatment of all Subjects under the Study and provide standard care cost of which shall be borne by the CRO.**

B. **Performance of the Study.** The Principal Investigator shall conduct the Study solely at the Institution. The Principal Investigator shall exercise due care in the conduct of the Study, and represent and warrant that it will be conducted in accordance with (i) generally accepted standards of good clinical and research practice (including, without limitation, the guidelines set forth by the International Conference on Harmonization, if applicable); (ii) this Agreement; (iii) the Protocol; (iv) written instructions provided by the Sponsor or Sponsor's designee; and (v) all applicable local, state and federal laws, regulations, and policies governing the performance of clinical investigations, including, but not limited to local regulatory requirements. In the event of a conflict between any requirements in (i) through (v) above, the Principal Investigator shall comply with the most stringent requirement. The Principal Investigator shall make no changes to the Protocol, except as agreed to and approved in writing by the Sponsor and, where required, the IEC / IRB. Neither the Institution nor the Principal Investigator shall subcontract any of its obligations or any portion of this Agreement to any other individual or entity without the prior written consent of the Sponsor.

C. **Key Personnel.** The Parties acknowledge that the participation of the Principal Investigator is essential to the successful performance and completion of the Study. If, for any reason, the Principal Investigator withdraws from the Study, becomes unavailable, or is otherwise unable to complete his responsibilities under this Agreement, the Principal Investigator shall immediately notify the Sponsor or Sponsor's designee and the Sponsor or Sponsor's designee shall endeavor to agree upon a successor. Absent prompt agreement upon a successor, the Sponsor may terminate this Agreement as set forth in Clause 12(B) below.

D. **Sponsor Visits.** The Sponsor's representatives may conduct periodic visits, at mutually acceptable times during normal business hours, to: (i) inspect and examine the Institution's facilities at which the Study is being conducted or was conducted; (ii) review the progress of the Study (including without limitation all source documents and data, and correspondence involving the IEC / IRB and applicable regulatory agencies); (iii) inspect and copy, at Sponsor's expense, any or all written and electronic data and work product relating to the Study; and (iv) collect financial billing and economic outcomes (including expense reports) provided that collection of such information is clearly described in the Informed Consent Form and appropriately authorized by the Subject and the IEC / IRB. The Principal Investigator and the Institution shall cooperate with the Sponsor and use reasonable efforts to promptly provide all of the information requested by the Sponsor.

The Institution and the Principal Investigator shall also cooperate with the Sponsor and with any regulatory agencies in the event of announced or unannounced monitoring, audit or inspection by such regulatory agencies. The Institution and the Principal Investigator shall notify the Sponsor by telephone of the intended or possible inspection within **twenty four (24) hours** of becoming aware of it; in addition, notice of the intended or possible inspection shall be sent to Sponsor **within forty eight (48) hours** of the telephonic notification. If a written response is required, the Institution and Principal Investigator shall permit representatives of the Sponsor to review and comment on such response prior to its being sent to the regulatory agencies. The Institution and Principal Investigator shall provide Sponsor with a copy of any report received in connection with, or as a result of such inspection **within three (3) day** of its receipt.

E. **Supplies.** The Sponsor or Sponsor's designee shall supply to the Principal Investigator, at no charge, sufficient quantity of the Study Drug to conduct the Study, as well as the materials, equipment and information which the Protocol specifies. The Principal Investigator acknowledges that the Study Drug is experimental in nature, and therefore shall use prudence and reasonable care in the use, handling, storage, transportation, disposition and containment of the Study Drug and any of its derivatives. Within 30 (thirty) days following the completion or termination of the Study, all unused Study Drugs, devices and other

materials that were furnished to the Institution by or on behalf of Sponsor shall, at Sponsor's expense, be returned to Sponsor, or if Sponsor so directs destroyed in accordance with instructions provided by the Sponsor. The Sponsor shall solely own all rights, title and interest in the Study Drug, including any materials derived therefrom and all intellectual property rights therein. The transfer of physical possession of the Study Drug hereunder, and/or the possession or use of the Study Drug by the Principal Investigator, shall neither constitute nor be construed as a sale, lease, or offer to sell or lease the Study Drug or other transfer of title in or to the Study Drug. Further, the Principal Investigator shall use the Study Drug solely for the conduct of the Study and in accordance with the Protocol unless they obtain the prior written authorization of the Sponsor.

F. Study Records, Reports, and Data.

i. *Study Records.* The Principal Investigator and the Institution shall, in a timely manner, prepare and maintain complete and accurate Study records as set forth in the Protocol and as may otherwise be required by applicable law, rule, regulation and good clinical practice (**"Study Records"**). The Principal Investigator shall make all Study Records, including, without limitation, source documents, signed Informed Consents, laboratory data, Drug inventory records, available to representatives of the Sponsor at the Sponsor's request. Except as otherwise expressly provided for in the Protocol or elsewhere herein, all Study Records shall be retained by the Principal Investigator for a period of **two (2) years** after the approval of the Study Drug for marketing or the formal discontinuation of the clinical development of the Study Drug or as per instruction given by CRO/ sponsor for the same or as per applicable regulatory requirement. Thereafter, prior to the disposal of the Study Records, Principal Investigator (as applicable) shall give the Sponsor not less than sixty (60) days prior express written notice thereof, and if the Sponsor requests in writing, the Principal Investigator shall transfer the Study Records to the Sponsor at Sponsor's expense. Study Records shall in no event be destroyed without Sponsor's prior written permission.

ii. *Case Report Forms.* The Principal Investigator shall complete full clinical evaluations and original CRFs on each Subject in accordance with the Protocol. The Principal Investigator shall ensure the accuracy, completeness, legibility and timeliness of the data reported to the Sponsor in the CRFs and in all required reports. In addition, the Principal Investigator shall deliver to the Sponsor or Sponsor's designee each completed CRF from monitoring visits as provided for in Clause 2(C) of this Agreement.

iii *Annual Reports*
The Principal Investigator shall submit written summaries of the status of the Study to the IEC / IRB annually, or more frequently, if requested by the IEC / IRB.

Iv *Final Reports*
Upon completion of the Study, the Principal Investigator will provide a summary of the Study's outcome (**"Final Report"**) to the IEC / IRB. In addition, any Serious Adverse Events will be reported to the IEC / IRB.

G. Reporting of Serious Adverse Event. The Institution and Principal Investigator shall notify Sponsor of any Serious Adverse Event encountered in the Study within twenty four (24) hours of becoming aware of it in accordance with the instructions set forth in the Protocol. Each such notice shall be given by fax/ mail, whether or not notification was initially given by telephone. The SAE reporting and follow up would be as per the current local applicable regulatory requirements.

5. CONFIDENTIALITY

A. Confidential Information: The term "Confidential Information" shall mean any and all information, data or know-how, trade secrets whether written or oral, technical or non-technical, as well as tangible materials including without limitation (i) financial, accounting, and business information, (ii) information relating to samples, compounds, procedures, Protocol, the Study Drug and all reports, documents, data and other information generated in connection with the Study or other information which the Institution or the Principal Investigator receives, directly or indirectly, from Sponsor and/or CRO and (iii) any other data or

information that is generated by the Institution as required by the Protocol and/or this Agreement, including Case Report Forms, laboratory data and Study results, but not including the medical records of the Institution. Subject to the provisions of Clause 5(A)(*i*) through 5(A)(*iv*), the Parties shall not disclose Confidential Information without prior written authorization from the Disclosing Party for any purpose other than those specified in this Agreement. The obligations of non-disclosure shall not apply to the following:

i. Confidential Information that is already in the public domain at time of disclosure or becomes publicly available through no fault of the Receiving Party;

ii. Confidential Information that is already known to or independently developed by the Receiving Party as shown by its prior written records, provided that Receiving Party informs the Disclosing Party promptly upon the Receiving Party's discovery that the Confidential Information is already independently known to the Receiving Party;

iii. Confidential Information that lawfully and in good faith received from a third party who did not derive it, directly or indirectly, from the Disclosing Party; and

iv. Confidential Information required to be disclosed to a governmental or regulatory agency to the extent necessary for the required disclosure.

Disclosing Party: The term "Disclosing Party" shall mean the Party disclosing Confidential Information to other Party.

Receiving Party: The term "Receiving Party" shall mean the Party receiving Confidential Information from the other Party.

B. Notwithstanding anything to the contrary in this Agreement, nothing herein shall (i) prevent the Institution from disclosing to the DCGI or any other appropriate regulatory agency Confidential Information (including Study results) that indicates that the administration or use of the Study Drug or device is associated with a serious risk of harm to the Subjects, provided that Institution furnishes at least fourteen (14) days advance written notice to the Sponsor and Sponsor fails during such time to either make the disclosure requested by Institution or to adequately demonstrate to the Institution that it has complied with all applicable disclosure requirements, or (ii) prevent Institution and/or Principal Investigator from informing the Subjects or potential Subjects of any adverse experiences or risks associated with the Study Drug or device.

C. **Non-Disclosure and Non-Use.** Except as otherwise expressly provided herein, for the term of this Agreement, and for a period of five (5) years thereafter, the Parties shall not disclose to any third party Confidential Information and shall not use for any purpose other than as expressly provided for herein any such Confidential Information, without the express written consent of the Disclosing Party. Without limiting the foregoing, the Parties shall disclose Confidential Information only to those employees of the respective Party who require such Confidential Information for the purposes of this Agreement and who are bound by an obligation of confidentiality and non-use no less stringent than set forth herein. Upon disclosing Confidential Information to any employee, the employing Party shall advise them of the confidential nature of the information, and shall require them to take all necessary and reasonable precautions to prevent the unauthorized disclosure thereof. In the event that the Parties are required to disclose Confidential Information pursuant to an order or requirement of a court, administrative agency, or other governmental body, the Parties, as the case may be, may disclose the Confidential Information provided that the Receiving Party provides the Disclosing Party with reasonable advance notice thereof to enable the Disclosing Party to seek an appropriate protective order or to prevent the disclosure. In such a situation, the Receiving Party shall provide reasonable assistance to the other Party to obtain a protective order or to prevent disclosure.

D. **Medical Confidentiality.** Notwithstanding any of the foregoing, Sponsor shall maintain the confidentiality of all medical records, case history, test reports, fitness data and charts to which it may have access in accordance with all applicable federal, state and local confidentiality laws and regulations and its corresponding regulations issued under DCGI or other applicable regulations. Sponsor shall not use, disclose, maintain, store, or transmit any individually identifiable Subject information except as permitted by such laws.

E. **Protection.** Without limiting the foregoing, the Parties shall maintain reasonable procedures to prevent accidental or other loss of any Confidential Information of the Disclosing Party, and shall use at least the same procedures and degree of care which each uses to protect its own confidential information, but in no case less than reasonable care. In the event of loss, disclosure or use of any Confidential Information in violation of this Agreement, the Receiving Party shall immediately notify the Disclosing Party. The Parties shall prevent the disclosure of medical records and private or personal information, whether confidential or not, to the extent required by applicable laws or regulations.

6. PUBLICATION

Subject to governing law, the Sponsor shall have the sole right to review, use, publish, and disclose any data, information, or results developed or arising out of the Study as the Sponsor, in its discretion, deems appropriate, including, without limitation, in submissions to the FDA and other governmental agencies. If Principal Investigator wants to publish his part, the prior written approval from Sponsor is required.

7. OWNERSHIP OF MATERIALS, DATA, INVENTIONS, AND DISCOVERIES

A. **Materials and Data.** The Sponsor shall solely own all right, title and interest in and to the Study Drug and any and all information, data or other materials delivered to the Institution or the Principal Investigator by or on behalf of the Sponsor as well as any derivatives, progeny, or improvements developed therefrom, and all intellectual property rights therein. Further, all data and work product arising out of or relating to the Study, including, without limitation, the Study Records, CRFs, reports, and specimens, and all intellectual property rights therein, shall be the sole property of the Sponsor. Accordingly, the Sponsor shall have, in its sole discretion, the right to publish, disclose, disseminate, and use, in whole or in part, the same for any and all purposes, including, without limitation, in and for submissions to the FDA or other regulatory agencies.

B. **Patents and Inventions.**

i. All right, title and interest in and to, whether domestic or foreign any inventions or discoveries (collectively, **"Inventions"**) first conceived of and reduced to practice prior to the Effective Date of this Agreement by the Principal Investigator, Institution or CRO as expressed in protocols, lab notebooks, or other written records, the know-how incidental thereto, and any patent applications and resulting patents derived there from shall be the exclusive property of that Party.

ii. "New Invention or Discovery" shall mean any invention or discovery conceived and reduced to practice during and as a part of Study by the Principal Investigator or any faculty, staff, employees, students or agents of the Institution or the Principal Investigator, or jointly by such an individual or individuals with one or more employees or consultants of the Sponsor.

iii. New Inventions or Discoveries made jointly by the Institution, Principal Investigator, or any of their respective agents with one or more employees or consultants of the Sponsor that: (a) are improvements to, new uses of, or (where applicable) new dosages or dosage forms of the Study Drug or device that arise from the performance of the research; or (b) occur during the performance of the Study and are based upon or subject to the claims of Sponsor's patentable Inventions shall be the sole property of Sponsor.

iv. New Inventions or Discoveries arising out of the research performed under this Agreement solely by Institution, Principal Investigator, and/or any of their respective agents that is not covered by the provisions of Clause 7(B)(*iii*) (an **"Institution Invention"**) shall be the sole property of Institution (subject to any agreement between the Institution and Principal Investigator regarding the ownership of inventions).

v. Institution and / or the Principal Investigator shall promptly notify the Sponsor a full written description of any New Inventions or Discoveries described in either Clause 7(B)(*iii*) or 7(B)(*iv*) of which they become aware. Sponsor shall have a time-limited, first option to negotiate an exclusive,

worldwide, royalty-bearing license to any Institution Invention. Any such exclusive license shall include a reasonable royalty based on Sponsor's and Institution's respective contributions to Institution Invention and other terms that are typical in licenses of similar technology. Sponsor shall advise Institution in writing of its interest in obtaining an exclusive license to any Institution Invention within sixty (60) days of Sponsor's receipt of notice of Institution Invention. If Sponsor fails to notify the Institution within sixty (60) days or provides notice that it elects not to obtain an exclusive license, then Sponsor's option shall expire with respect to that particular Institution Invention and Institution shall be free to dispose of its interest in accordance with its technology transfer policies. If Sponsor and Institution fail to reach agreement on the terms for an exclusive license of a particular Institution Invention within four (4) months after Sponsor provides notice that it wishes to exercise its option, then for a period of one (1) year thereafter, the Institution shall not offer to license the Institution Invention to any third party on materially better terms than those last offered to the Sponsor without first offering such terms to Sponsor, in which case Sponsor shall have a period of thirty (30) days to accept the offer.

C. **No Other Rights.** Except as expressly set forth herein, none of the Sponsor, the Principal Investigator, or the Institution transfers to any other Party hereto, by operation of this Agreement or otherwise, rights to any patent, copyright, trademark or other intellectual property right of any kind.

8. REPRESENTATIONS, WARRANTIES AND COVENANTS

A. **Of the Principal Investigator.** The Principal Investigator represents and warrants that (i) he has the legal authority and right to enter into this Agreement; (ii) he has no obligation to any third party that is in conflict with, or has the potential to conflict with, its obligations under this Agreement; (iii) he has and will maintain throughout the conduct of the Study, all training, information, licenses, approvals and certifications necessary for safely, adequately, and lawfully performing the Study; (iv) he will not enter into any agreement with any third party to directly or indirectly fund or support the Study without the express written consent of the Sponsor (excluding laboratory investigations, radiological investigations or any other requirement to fulfill Protocol criteria), and (v) this Agreement has been duly executed and delivered by it and constitutes a valid, binding obligation enforceable against it in accordance with its terms.

The Principal Investigator represents and warrants that no clinical study or trial in which he was involved was terminated for any reason prior to completion that was due, in whole or in part, to the Principal Investigator's non-compliance with the applicable protocol and/or safety requirements of the study or any applicable local, state or federal law. The Principal Investigator further represents and warrants that he has not received any written notice from the DCGI/FDA or NIH of any violation of any applicable federal law relating to clinical studies that has not been disclosed to the Sponsor and attached to this Agreement as an Exhibit hereto. For the purposes of the prior sentence, "written notice" shall include, but not be limited to, DCGI or FDA lists of Inspectional Observations (FDA Form 483), Notices of Adverse Findings, regulatory letters, warning letters, notices of intent to initiate clinical investigator disqualification proceedings under national regulations or under 21 C.F.R. 312.70 or 21 C.F.R. 812.119 or any similar regulation (**"Notice of Intent to Disqualify"**). The Principal Investigator further represents and warrants that he has never been disqualified from receiving investigational drugs or medical devices by the DCGI or FDA or NIH or any other federal governmental body. In the event that any of the foregoing events in this paragraph occur during the course of this Study, the Principal Investigator shall provide the Sponsor with a full written explanation of the circumstances of such an incident within ten (10) days of the occurrence of such an incident. If the Institution or the Principal Investigator becomes debarred as per the national or local regulations, this Agreement will immediately terminate. If the Principal Investigator receives a notice or threat of action with respect to its debarment or a Notice of Intent to Disqualify, the Sponsor shall have the right to terminate this Agreement immediately without further cost or liability. The Principal Investigator represents and warrants on his own behalf that he has not used, in any capacity, the services of any individual, corporation, partnership, or association which has been debarred, and neither shall use, in any capacity, the services of any individual, corporation, partnership, or association which has been debarred. In the event that the Principal Investigator becomes aware of the debarment or threatened debarment of any individual, corporation, partnership, or association providing services to the Principal Investigator which directly or indirectly relate to Principal Investigator's activities under this Agreement, the Principal

Investigator shall notify the Sponsor immediately and the Sponsor shall have the right to terminate this Agreement immediately without further cost or liability.

B. **Of the Sponsor.** The Sponsor represents and warrants that (i) it has the legal authority and right to enter into this Agreement, (ii) it has no obligation to any other party that is in conflict with the Sponsor's obligations under this Agreement, and (iii) this Agreement has been duly executed and delivered by it and constitutes a valid, binding obligation enforceable against it in accordance with its terms.

Sponsor represents and warrants to Institution and Principal Investigator the following: (i) any Study Drug or device administered or used in carrying out the Protocol has been approved by the DCGI or FDA or by the other regulatory agencies if applicable for investigational use; and (ii) Sponsor has at all times complied with and will continue to comply with all DCGI or FDA and comparable foreign rules, regulations, requirements, and guidelines regarding administration, manufacture, and production of drugs and devices under regulatory control of the DCGI or FDA and/or comparable foreign agencies in connection with any drug or device administered or used pursuant to the Protocol. In particular, Sponsor shall comply with all DCGI or FDA reporting rules that require it to inform Institution and/or Principal Investigator of any serious and unexpected adverse experience associated with the Study Drug or device.

C. **No Other Representations or Warranties.** Except for the limited representations and warranties given in this Clause 8, none of the Sponsor, the Institution, or the Principal Investigator makes or receives any representations or warranties, express or implied, statutory or otherwise, and each expressly disclaims any implied warranties of merchantability, fitness for a particular purpose, or non-infringement.

9. GOVERNING LAW

This Agreement shall be governed by and construed in accordance to the Laws of India. Disputes, if any, shall be arbitrated upon under the Arbitration and Conciliation Act, 1996 in English language and the venue shall **be Meerut, UP, India**. It is expressly agreed that the arbitral award shall be final and binding upon both the Parties hereto. However, the final jurisdiction shall lie with the **courts of Meerut, UP, India**. Each of the Parties hereby expressly submits to the jurisdiction of the courts of **Meerut**, India.

10. INDEMNIFICATION

A. **Sponsor Indemnification.** The Sponsor shall defend, indemnify, and hold harmless the Institution and its trustees, officers, the Investigators, employees and agents (the **"Institution Indemnities"**) from and against any liability, loss, damage, or expense (including reasonable attorneys' fees and expenses of litigation) incurred by or imposed upon the Institution Indemnities or any one of them in connection with any third party claims, suits, actions, demands, or judgments but only to the extent such claims, suits, actions, demands or judgments arise from or are caused by the Study Drug or study related procedures and are not covered by insurance or self-insurance as set forth in Clause 11 and provided that the Study is conducted in accordance with (i) this Agreement and the Protocol; (ii) all written instructions provided by the Sponsor concerning the Study; (iii) all applicable federal, state, or local laws, rules, regulations, requirements, and policies; and (iv) the manner required of reasonable and prudent clinical investigators and physicians; and such loss does not arise out of the negligent or reckless conduct or omission or intentional misconduct or malfeasance of any Institution Indemnities, or any other person on the Institution's property or under its control, exclusive of the Sponsor's employees; and the Sponsor is notified within ten (10) working days of any complaint, claim, or injury relating to any loss for which indemnification and/or defense under this Agreement might be sought; and Principal Investigator and the Institution and its directors, officers, and employees fully cooperate with the Sponsor and its legal representatives in the investigation and defense of any claim or suit covered under this Agreement.

B. **Institution Indemnification**. The Institution shall defend, indemnify, and hold harmless the Sponsor and its affiliates and their respective directors, officers, employees, agents, successors, and assigns (**"Sponsor Indemnities"**) from and against any and all third party liability, loss, damage, or expense (including reasonable attorneys' fees and expenses of litigation) incurred by or imposed upon the Sponsor Indemnities or any one of them in connection with any third party claims, suits, actions, demands, or judgments to the

extent such claims, suits, actions, demands, or judgments arise out of: (i) a failure to conduct the Study in accordance with this Agreement and the Protocol, all written instructions provided by the Sponsor concerning the Study, all applicable federal, state, or local laws, rules, regulations, requirements, and policies, and in the manner required of reasonable and prudent clinical investigators and physicians; and (ii) the negligent or reckless conduct or omission or intentional misconduct or malfeasance of any Institutional Indemnity, or any other person on the Institution's property or under its control, exclusive of the Sponsor's employees.

C. **Notification.** The Parties shall promptly notify each other of any such claims, suits, actions, demands, or judgments and the Parties shall reasonably cooperate with each other in the handling thereof.

D. **Claims.** The indemnifying Party, at its own expense, shall have the exclusive right to manage claims, control investigation and litigation, and select counsel, including the right to compromise or settle any claims, actions, suits, demands, or judgments, provided that it shall not compromise or settle any such action with an admission of liability or wrongdoing by the indemnified Party without such Party's written consent.

E. **Representation.** In the event a claim or action is or may be asserted, the non-indemnifying Party shall have the right to select and obtain representation by separate legal counsel. If the non-indemnifying Party exercises such right, all costs and expenses incurred by the non-indemnifying Party for such separate counsel shall be fully borne by the non-indemnifying Party; provided, that without the Indemnifying Party's prior written consent, the non-indemnifying Party shall make no admission to, or any settlement or agreement with, any person or party who is in any manner related to the liabilities for which indemnification may be sought by an non-indemnifying Party Indemnity.

G. **Subject Injury.** The Sponsor shall reimburse the Principal Investigator or the Institution for reasonable and necessary medical expenses that are directly and reasonably incurred by Subjects in the treatment of adverse events caused by the Study Drug or Study related procedures following their administration or use in accordance with the Protocol and that are not covered by the Subject's insurance or governmental programs providing such coverage, provided that such expenses are not attributable to the negligence or misconduct of the Principal Investigator or any agent or employee of the Institution or other person engaged in performing the Study; and provided further that such expenses are not attributable to a failure of the Principal Investigator or any agent or employee of Institution to conduct the Study in accordance with (i) this Agreement; (ii) the Protocol; (iii) all written instructions delivered by the Sponsor concerning administration of the Study Drug; (iv) all applicable government laws, rules, regulations, requirements, and policies; and (v) the manner required of a reasonable and prudent clinical investigator or physician; and provided, further, that the Sponsor shall not be obligated to reimburse the Institution for such costs if such illness or injury arises out of or is related to a pre-existing abnormal medical condition or underlying disease of the Subject. Institution and Principal Investigator shall ensure that the amounts charged to the Sponsor in connection with such reimbursed treatments do not exceed the reasonable and customary amount allowed by Institution to any third party for such treatments. All such payments by the Sponsor shall be secondary to the insurance of the Subject and contingent on the Subject reasonably cooperating with the Sponsor's investigation of the injury and its causes. Subject shall be entitled to financial compensation from the Sponsor, Institution or the Principal Investigator in case of injury or death during clinical trial in accordance with Rule 122DAB of Drugs and Cosmetics Rules, 1945 as may be amended from time to time.

11. INSURANCE

A. **Sponsor Insurance.** Sponsor shall maintain during the term of this Agreement and for a period of One (1) year thereafter, general liability insurance (with product liability endorsements) and professional clinical trial liability insurance coverage sufficient to meet its indemnification obligations in the amount of **INR 12,00,00,000/- (INR Twelve Crore Only)** in the aggregate. Sponsor will provide evidence of its insurance upon request and will provide to the Institution, thirty (30) days prior written notice of cancellation of its coverage. Sponsor further agrees to include Institution and Principal Investigator as additional insured on such policy.

B. **Institution Insurance.**
Institution and Principal Investigator shall maintain during the term of this Agreement, general liability insurance and professional liability insurance coverage sufficient to meet its indemnification obligations on appropriate conditions and will provide to Sponsor and CRO thirty (30) days prior written notice of cancellation of its coverage.

This Clause 11 shall survive termination of this Agreement.

12. TERM AND TERMINATION

A. **Term.** This Agreement shall begin on the Effective Date and shall remain in full force and effect until the completion of the Study and the submission of the Final Report pursuant to Clause 4(F)(*iv*), above, unless earlier terminated in accordance with this Agreement.

B. **Termination.**

i. Either Party may terminate this Agreement immediately upon written notice to the other if:

a. the authorization and approval to perform the Study in India is withdrawn by the DCGI and/or other applicable regulatory authority in India;

b. animal, human and/or toxicological test results, in the opinion of either Sponsor or Institution, support termination of the Study; or

c. the circumstances require termination of Study in order to protect the safety, rights, or welfare of Subjects enrolled in the Study. In the alternative, either Party may immediately dis-enroll any Subject to protect that Subject's safety, rights or welfare without terminating this Agreement, but shall promptly give the other Party written notice of the dis-enrollment.

ii. This Agreement may be terminated by either party, upon thirty (30) days prior written notice, if either of the following conditions occurs:

a. if either Party fails to comply with the terms of this Agreement within thirty (30) days of receipt of written notice, with opportunity to cure, from the other Party; or

b. if the Principal Investigator is unwilling or unable to continue to serve and a successor acceptable to both Institution and Sponsor is not available.

iii. This Agreement may be terminated by either Party for any reason other than those listed in Clause 12(B) upon thirty (30) days prior written notice.

iv. Upon the effective date of termination, there shall be an accounting conducted by Institution, subject to verification by Sponsor. Within thirty (30) days after receipt of adequate documentation there from, Sponsor will make payment to Institution for:

a. all services properly rendered and monies properly expended by the Institution until the date of termination not yet paid for; and

b. reasonable non-cancelable obligations properly incurred for the Study by Institution prior to the effective date of termination.

v. Immediately upon receipt of a notice of termination, the Principal Investigator shall stop enrolling Subjects into the Study and shall cease conducting procedures on Subjects already enrolled in the Study as directed by Sponsor, to the extent medically permissible.

vi. **Immediate Termination by the Sponsor.** The Sponsor may terminate this Agreement, in whole or in part, effective immediately, upon written notice to the Principal Investigator; a) if the Sponsor, in its sole discretion, deems that the safety of the Subjects will be compromised by a delay in termination; or b) for any violation of the Study Schedule set forth in Clause 2) prior to the shipment of the Study Drug to the Institution.

vii. **Effect of Termination.** In the event this Agreement is terminated prior to completion of the Study, for any reason, the Principal Investigator shall a) notify the IRB that the Study has been terminated; b) cease enrolling Subjects in the Study; c) cease treating Subjects under the Protocol as directed by the Sponsor to the extent medically permissible and appropriate, and d) terminate, as soon as practicable, but in no event more than thirty (30) days after the effective date of termination, all other Study activities; provided, however, upon the Sponsor's request, the Institution and the Principal Investigator shall continue to collect data and prepare and complete CRFs for Subjects treated in the Study prior to termination. Within ninety (90) days from the effective date of any such termination, the Institution and the Principal Investigator shall provide to the Sponsor all data collected in connection with the Study, including, without limitation, Study reports and the Final Report described in Clause 4(F), above, and, except as otherwise provided herein, shall return to the Sponsor any and all materials and Confidential Information provided by the Sponsor for the conduct of the Study, at the Sponsor's expense, provided, however, that the Institution may retain one (1) copy of the Confidential Information for record keeping purposes. The Sponsor shall remain liable for payment for any CRFs submitted prior to the effective date of termination, or within ninety (90) days thereafter, in compliance with the terms of this Agreement.

viii. **Survival.** Termination of this Agreement by either Party shall not affect the rights and obligations of the Parties accrued prior to termination. All provisions in this Agreement which, by their nature, extend beyond termination of the Agreement, together with the provisions of Clauses 4(F), 5, 6, 7, 9, 10, 11,and 12 shall survive any termination of this Agreement for any reason.

13. MISCELLANEOUS

A. **Use of Names; Publicity.** Except as otherwise required by applicable law, regulation or court order, no Party to this Agreement will use the name or other identifying marks of any other Party or its affiliates or its employees in any advertisement, press release, or other public statement without prior written approval of the other Party; provided however that Sponsor may identify the Institution as a participating clinical site and the Principal Investigator as an investigator in a Study. The Institution and the Principal Investigator shall have the right to acknowledge the Sponsor's support of the research performed under this Agreement in scientific publications and other scientific communications (any such publications or communications shall be made in accordance with Article 6). Each of the Parties hereto shall not disclose to any third party the terms of this Agreement without the prior written consent of the other Party, except to advisors, investors, and others on a need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law, regulation or court order.

B. **Independent Contractors.** The Parties acknowledge that the relationship between the Sponsor, CRO, Institution and Principal Investigator created by this Agreement is that of independent contractors and that neither the Principal Investigator nor Institution or CRO may create or assume any obligation on behalf of the Sponsor.

C. **Limitation of Liability.** In no event shall the Parties be liable to each other for any special, incidental, or consequential damages arising out of or relating to this Agreement, or the subject matter hereof, however caused and whether such claim is based in contract, tort (including negligence), or otherwise, even if an authorized representative of the Sponsor is advised of the possibility of such damages.

D. **Notices.** Any notices required or permitted to be given hereunder shall be in writing, shall be addressed to the Party to whom such notice is intended as follows, or such other address and/or number as such Party may substitute by written notice hereunder, and shall be effective on receipt.

Any notice to the Sponsor shall be addressed as follows:

Address: Cipla Limited, Cipla House,
Peninsula Business Park,
Ganpatrao Kadam Marg,
Lower Parel, Mumbai - 400 013.

Attention: Ms. Pallavi Phopale
Email: pallavi.londhe@cipla.com
Contact: 022-25787825

Any notice to Institution shall be addressed as follows:

Address: SUBHARTI MEDICAL COLLEGE,
Subharti Puram, NH-58,
Delhi Haridwar Bypass Road,
Meerut, Uttar Pradesh 250005
Attn: Dr. Hira Lal Bhalla
(Phone/mobile): +91- 9761715236

Any notice to Principal Investigator shall be addressed as follows:

Address: SUBHARTI MEDICAL COLLEGE,
Subharti Puram, NH-58,
Delhi Haridwar Bypass Road,
Meerut, Uttar Pradesh 250005
Attn: Dr. Shashi Prateek , Dr Hira Bhalla
(Phone/mobile): +91- 9313700855, 9761715236

Any notice to CRO shall be addressed as follows:

Cliantha Research Ltd.,
Garden View Corporate House No.8,
Opposite Auda Garden,
Bodakdev, Ahmedabad- 380054

Attn: Dr. Chirag Shah, Associate Director – Clinical Trials
+91-79-66219531 (phone)
+91-79-66219549 (fax)"

E. **Assignment.** This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their respective successors, assigns, legal representatives and heirs. The Sponsor may assign this Agreement to any successor to all or substantially all of the business of the Sponsor, or in connection with its merger, consolidation, change in control or similar transaction. Except as otherwise set forth above, this Agreement may not otherwise be assigned by a Party (whether voluntarily, by operation of law or otherwise) without the prior written consent of the other Parties. Any purported assignment of this Agreement in violation of this section shall be void.

F. **Modification; Waiver.** This Agreement may not be altered, amended or modified in any way except in writing signed by the Sponsor, the Institution and the Principal Investigator. The failure of a Party to enforce any provision of the Agreement shall not be construed to be a waiver of the right of such Party to thereafter enforce the provision or any other provision or right.

G. **Entire Agreement.** This Agreement and its Exhibits constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior discussions, negotiations, communications, understandings, agreements, representations and writings with respect to all matters covered by the Agreement. In any conflict between the terms of this Agreement and the documents incorporated herein, the terms of this Agreement shall take precedence except as otherwise specifically set forth in this Agreement.

H. **Severability.** In the event that any provision of this Agreement is determined to be illegal, invalid or unenforceable by a court of competent jurisdiction, the remainder of this Agreement shall remain in full force and effect without said provision. The Parties shall negotiate in good faith a substitute clause for any provision declared illegal, invalid or unenforceable, which shall most nearly approximate the original intent of the Parties in entering this Agreement.

I. **Execution.** The Institution's IRB shall be the authorized representative of the Institution to approve the Protocol and any amendments thereto. This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same agreement. This Agreement may be executed by facsimile signature.

J. **Changes to the Protocol.** If at a future date changes in the Protocol appear desirable, such changes may be made through prior written agreement between Sponsor and Institution. If such changes affect the cost of the Study, Institution will submit to Sponsor a written estimate for approval. If in the course of performing this Agreement, however, generally accepted standards of clinical research and medical practice relating to the safety of Subjects require a deviation from the Protocol, such standards will be followed. In such case, the Party aware of the need for a deviation will immediately inform the other of the facts causing such deviation as soon as the facts are known to the Party.

K. **Covenant Not to Hire**. Sponsor shall not, and shall not permit any of its affiliates to, employ or offer to employ any Key Personnel (as defined in this Section) until one year following termination or expiration of this Agreement, unless Institution, or Institution's affiliate, as the case may be,.

gives its written consent thereto. "Key Personnel" shall mean those individuals employed by Institution, who perform research related services for Institution or any of its affiliates, including, but not limited to, persons serving as research coordinators and grant account managers.

L. **Drug Safety and Reporting.** The recording of adverse events (AEs) is an important aspect of the Study documentation. It is the Principal Investigator's responsibility to document all AEs according to the detailed guidelines of the Protocol and current applicable local regulatory requirements. The Principal Investigator agrees to answer any questions of SPONSOR and/or CRO's Medical Monitor concerning any AEs. According to the Protocol, the Principal Investigator will assess at each visit whether any adverse event (AE) including abnormal laboratory values has occurred. The details of all AEs, whether reported by the Subject or observed by the Principal Investigator / Study personnel during the entire Study, will be recorded onto the appropriate source document. Each adverse event must be recorded in the AE section of the case report form (CRF), regardless of the causal relationship.

The Principal Investigator must immediately report all serious adverse events (as defined in Protocol), which occur during the course of the Study and up to the date of the Subject's last visit, to the addressee given below. The SAE Report form will be used for documentation and reporting.

Initial and follow up SAE reports are to be faxed to the Medical Affairs Department of CRO for onward transmission to SPONSOR:

Name:	Dr. Ripal Gharia
SAE Fax number:	+91-79-66219549
Telephone numbers:	+91-79-66219543
Cell number:	+91 9016435609
E-mail:	rgharia@cliantha.in

If the event is unexpected and fatal or life threatening and is considered by the Principal Investigator possibly related to the Study medication, the Drug Safety Department of CRO shall be informed immediately by telephone and followed immediately by fax.

CRO undertakes to notify the Principal Investigator and SPONSOR of all serious unexpected adverse events, which occur during the course of the Study in any other location and are reported in an expedited manner to health authorities. The Principal Investigator will inform the local ethics committee of SAEs reportable according to its national requirements and timelines, and of findings that could adversely affect the Subject's safety, could have an impact on the conduct of the Study, or could alter the ECs / IRB's approval to continue the Study.

CRO will be responsible to notify on time the health authorities in India.

IN WITNESS WHEREOF, the undersigned have entered into this Agreement as of the date first set forth above.

INSTITUTE

By: _____
(Signature)

Dr. A.K. Asthana
(Printed Name)

Head of the Institute
(Title)

15 Nov 2016
(Date)

BY EXECUTING THIS DOCUMENT IN THE SPACE PROVIDED BELOW, THE PRINCIPAL INVESTIGATOR HEREBY ACKNOWLEDGES AND AGREES TO COMPLY WITH THE TERMS OF THIS AGREEMENT AND THE APPLICABLE PROTOCOL, AS AMENDED FROM TIME TO TIME

PRINCIPAL INVESTIGATOR

By: _____
(Signature)

Dr. Shashi Prateek
Principal Investigator

15.11.16.
(Date)

CLIANTHA RESEARCH LIMITED

By: _____
(Signature)

Dr. CHIRAG SHAH
Head of the Department, Clinical Trials

24/Oct/2016
(Date)

21/8/17

HDFC BANK

ROOM NO 001, PLATINUM PLAZA,
4, BODAKDEV II,AHMEDABAD-380054,GUJARAT
S / NEFT IFSC : HDFC0000783

Imperia

A/c Payee

Weekly Holiday on SUNDAY

28072017

Valid for 3 months only

Pay SUBHARTI K.K.B CHARITABLE TRUST

Or Bearer

या धारक को

Rupees रुपये Twenty Three Thousand Four Hundred Only

अदा करें ₹ **23,400.00

A/c. No. 07838630000031

Brn: 0783 Pdt:863
CA MAX

Payable at par through clearing/transfer at all branches of HDFC BANK LTD

For CLIANTHA RESEARCH LIMITED

Authorised Signatories

Please sign above / कृपया यहाँ हस्ताक्षर करें

Dr. Shashi Prateek
Fibroid

⑈016761⑈ 380240014⑆ 005841⑈ 29

Protocol Cr/04/12.

The invoice generated includes the payments of Subject No. 1001 to 1021 for various schedules of investigations.

Thanks and regards

Dr H. L. Bhalla

Professor

Department of Pharmacology

Registrar
Swami Vivekanand
Subharti University
MEERUT

I NO 001, PLATINUM PLAZA,
IAKDEV ILAHMEDABAD-380054,GUJARAT
IFSC : HDFC0000783

A/c Payee

0 3 1 0 2 0 1 7
D D M M Y Y Y Y
Valid for 3 months only

IHARTI K.K.B CHARITABLE TRUST

Or Bearer

s रुपये Forty One Thousand Forty Only

या धारक को

अदा करें ₹ **41,040.00

lo. 07838630000031

Brn: 0783 Pdt:863
CA MAX

Payable at par through clearing/transfer at all branches of HDFC BANK LTD

For CLIANTHA RESEARCH LIMITED

Authorised Signatories

Please sign above /कृपया यहाँ हस्ताक्षर करें

⑈017198⑈ 380240014⑆ 00584⑆ 29

Registrer
Swami Vivekanand
Subharti University
MEERUT

Vishal Bang
B.Sc

Imperia

A/c Payee

Weekly Holiday on SUNDAY

1 3 1 1 2 0 1 7

D D M M Y Y Y Y

Valid for 3 months only

...TABLE TRUST

Or Bearer

या धारक को

...Thousand Forty Only

अदा करें

₹ **41,040.00

07830030000031

Brn: 0783 Pdt:003
CA MAX

Payable at par through clearing/transfer at all branches of HDFC BANK LTD

For CLIANTHA RESEARCH LIMITED

Authorised Signatories

Please sign above / प्राधिकृत हस्ताक्षर

"018154" 380240014: 005844" 29

Ch. Received thr. Gunjan Mittal F.O' on 27/11/17

Regarding Payment Received from CIPLA 27/11/17

उपरोक्त Voucher सत्यापित करके F.O. कृपया लिखा करें। 28/11/17

12

Registrar
Swami Vivekanand
Subharti University
MEERUT

HDFC BANK

SHOWROOM NO 001, PLATINUM PLAZA,
PART 4, SODAKDEV ELAHMEDABAD-380054,GUJARAT
RTGS / NEFT IFSC : HDFC0000783

A/c Payee

Weekly Holiday on SUNDAY

0	8	0	3	2	0	1	8
D	D	M	M	Y	Y	Y	Y

Valid for 3 months only

Pay SUBHARTI K.K.B. CHARITABLE TRUST Or Bearer

या धारक को

Rupees रुपये One Lakh Twelve Thousand Eight Hundred Sixty

Only अदा करें

₹ **1,12,860.00

A/c. No. खाता सं. 07838630000031

Brn: 0783 Pdt:863
MAX CA

Payable at par through clearing/transfer at all branches of HDFC BANK LTD

For CLIANTHA RESEARCH LIMITED

Authorised Signatories

Please sign above /कृपया यहाँ हस्ताक्षर करें

⑈019488⑈ 380240066⑈ 00584668⑈ 29

Fibroid Cipla
Dr. Shashi Prateek

Registrer
Swami Vivekanand
Subharti University
MEERUT

World Health Organization

COVERING LETTER
LETTRE D'ACCOMPAGNEMENT

WHO/GSC/GPI
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ *Référence OMS*

WHO Reference	2016/637886-0
Purchase Order	201522017
Reg. File	N/A
Unit Reference	MCA/MRD

DR Sunil Sawazal
CENTER FOR PUBLIC HEALTH KINETICS
VINOBAPURI,LA
214-A BASEMENT
VINOBA PURI,LAJPAT NAGAR-
100024
India

Téléphone Central/Exchange: +60 3 8871 7111
Email / Courriel: GSCprocurement@who.int

Re: ESTABLISHING THE OPTIMAL DOSE OF THERAPEUTIC ZINC SUPPLEMENTATION FOR THE TREATMENT OF ACUTE DIARRHEA IN UNDER FIVE CHILDREN - A DOSE RESPONSE TRIAL IN A SOUTH ASIAN AND A SUB-SAHARAN AFRICAN SETTING - ZINC THERAPEUTIC DOSING TRIAL (ZTDT)

We are enclosing the Technical Services Agreement between the World Health Organization and CENTER FOR PUBLIC HEALTH KINETICS, VINOBAPURI,LA, in the amount of INR 30,168,000.00 (Thirty Million One Hundred Sixty-Eight Thousand), for conducting the above-mentioned work. We also enclose one attachment(s) referenced in the Agreement.

We kindly request that you return, duly signed, a copy of the Agreement, keeping one copy for your files.

For any technical or scientific questions, please contact Jonathon SIMON, +1 617 417 1298, simonjo@who.int .

On behalf of the World Health Organization, we thank you for your collaboration.

WHO Global Service Centre

Cc: WHO Representative, India

Concerne: ESTABLISHING THE OPTIMAL DOSE OF THERAPEUTIC ZINC SUPPLEMENTATION FOR THE TREATMENT OF ACUTE DIARRHEA IN UNDER FIVE CHILDREN - A DOSE RESPONSE TRIAL IN A SOUTH ASIAN AND A SUB-SAHARAN AFRICAN SETTING - ZINC THERAPEUTIC DOSING TRIAL (ZTDT)

Veuillez trouver ci-joint l'Accord de Services Techniques entre l'Organisation Mondiale de la Santé et CENTER FOR PUBLIC HEALTH KINETICS, VINOBAPURI,LA, pour un montant de INR 30,168,000.00 (Thirty Million One Hundred Sixty-Eight Thousand), vous permettant de mener à bien le travail susmentionné. Veuillez également trouver one pièces jointes mentionnées dans l'Accord.

Veuillez nous retourner, dûment signée, une copie de l'Accord et en garder une pour vos dossiers.

Pour toutes questions à caractère scientifique ou technique, veuillez contacter Jonathon SIMON, +1 617 417 1298, simonjo@who.int

Au nom de l'Organisation Mondiale de la Santé, nous vous remercions de votre collaboration.

Centre de Soutien Administratif Mondial de l'OMS

Cc: Représentant de l'OMS, India

World Health Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ *Référence OMS*	
WHO Reference	2016/637886-0
Purchase Order	201522017
Reg. File	N/A
Unit Reference	MCA/MRD

TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES

The WORLD HEALTH ORGANIZATION hereby agrees to provide to
L'ORGANISATION MONDIALE DE LA SANTE s'engage par la présente à fournir à
INSTITUTION:

CENTER FOR PUBLIC HEALTH KINETICS
VINOBAPURI LA
Principal investigator
VINOBA PURI LAJPAT NAGAR-
India

Principal Investigator: DR.Sunil Sawazal
Telephone:
Fax:
Email/Courriel: admin@cphealthkinetics.org

The Amount of/*Un Montant de:* INR 30,168,000.00 (Thirty Million One Hundred Sixty-Eight Thousand)
in respect of/*en vue de:* ESTABLISHING THE OPTIMAL DOSE OF THERAPEUTIC ZINC SUPPLEMENTATION FOR THE TREATMENT OF ACUTE DIARRHEA IN UNDER FIVE CHILDREN - A DOSE RESPONSE TRIAL IN A SOUTH ASIAN AND A SUB-SAHARAN AFRICAN SETTING - ZINC THERAPEUTIC DOSING TRIAL (ZTDT)

For the period financed by this Agreement
Période du projet financée par le présent accord
From/*De* : 15-JUN-2016
To/*A* : 14-JUN-2017

Summary of work/ ***Description sommaire des travaux:***

1. Description of work under this Agreement/ *Description des travaux faisant l'objet du présent accord:*

The overall goals of this study are to:
- To evaluate the non-inferiority of two lower zinc doses (10 mg/day and 5 mg/day) versus standard zinc dose (20 mg/day) regarding diarrhoea outcomes (duration of symptoms, and risk of diarrhoea >5 days)
- To evaluate the safety of lower dose versus standard dose zinc regarding vomiting and other adverse events, and
- To evaluate the acceptability of lower doses versus standard dose zinc using an acceptability scale.

2. Contribution of the institution and/or other sources for the project (Staff, equipment, supplies, etc. excluding general facilities).
The Institute will provide all facilities, equipment and personnel not covered by this Agreement.
Contribution de l'Institution ou de tout autre organisme à l'exécution du projet (personnel, matériel, fournitures, etc. à l'exclusion des services d'ordre général): L'Institution s'engage à fournir les locaux, équipement et personnels non couverts par cet accord.

Financial Arrangements/ ***Dispositions financiers:***

1. Payments will be made as follows/*Les versements seront effectués comme suit:*

	Deliverable/ Résultat	Due Date/ *Date Remise*	%	Currency Amount/ *Montant en Devise*
1	Countersigned Contract	15-JUN-2016	100.00	30,168,000.00
2	On receipt of satisfactory technical and financial reports	30-MAY-2017	0.00	0.00

2. INR 0.00 will be used by WHO for the purchase of equipment and supplies to be ordered by the Institution as soon as practicable, but not beyond 31 December of the year following the end of the Agreement period as indicated above at which time any uncommitted balance will revert to WHO.

INR 0.00 seront affectés par l'OMS à l'achat de matériels et de fournitures à commander par l'Institution dès que possible, mais au plus tard avant le 31 décembre de l'année suivant la fin de la période susmentionnée d'exécution de l'accord, étant entendu qu'à ce moment tout solde non engagé fera retour à l'OMS.

Annexes

The following annexes form an integral part of this Agreement/ *Les annexes listées ci-dessous font partie intégrante de cet accord:*

Annex	File Description/Description de fichier
1	2016/637886 | Contractual - Terms of Reference |

In the event that the terms of the annexes contain any provisions which are contrary to the terms of this Agreement, the terms of this Agreement shall take precedence/ *En cas de contradiction entre les termes apparaissant sur les annexes et ceux de l'Accord, les dispositions de l'Accord prévaudront dans tous les cas.*

WHO Financial References/ ***Références financières de l'OMS***

	Project	Task	Award	Expenditure Type	Expenditure Organization	%	USD
1	HQMCA1611083	13.2	64435	512-Consulting Research Ser	HQ	100	450,000.00

World Health Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ *Référence OMS*	
WHO Reference	2016/637886-0
Purchase Order	201522017
Reg. File	N/A
Unit Reference	MCA/MRD

TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES

General
The parties accept the "General Conditions" overleaf, which constitute an integral part of this Agreement. The Institution certifies the correctness of the banking instructions provided on Page 1.
All necessary arrangements to comply with national regulations relating to this project and relevant to the Institution's responsibilities shall have been undertaken by the Institution; failure to do so will nullify this Agreement. The responsibility of the World Health Organization is limited only to the financial support as specified in this Agreement.

Généralités
Les parties acceptent les "Conditions générales" reproduites au verso, lesquelles font partie intégrante du présent accord. L'Institution certifie l'exactitude des instructions bancaires indiquées à la page 1.
Toutes les dispositions relevant des responsabilités de l'Institution et nécessaires à la mise en conformité de ce Projet avec la réglementation nationale, devront avoir été prises par l'Institution; faute de quoi l'accord sera nul. La responsabilité de l'Organisation Mondiale de la Santé se limite au soutien financier spécifié dans le présent accord.

ON BEHALF OF WHO/ *POUR L'OMS*

Responsible WHO Technical Officer:
Fonctionnaire technique responsable de l'OMS:

Jonathon Simon
Scientist
HQ/MCA Maternal, Newborn, Child and Adolescent Health

Responsible Divisional Director
Directeur de division responsable

Flavia BUSTREO
Asst Director-General
HQ/FWA FWC ADGO Office of the Assistant DG

Authorized Signatory
Signataire autorisé

Mr Motohiro Ogita
Coordinator
Global Procurement and Logistics
(WHO/GMG/GSC/GPL)

Motohiro Ogita
Coordinator
HQ/GSC Global Service Centre
15 JUN 2016

PRINCIPAL INVESTIGATOR/ *CHERCHEUR PRINCIPAL*

Principal Investigator or Technical Officer responsible for the project.
Chercheur Principal ou membre du personnel technique responsable de l'exécution du projet

Signature :
DR Sunil Sazawal

ON BEHALF OF THE INSTITUTION/ *POUR L'INSTITUTION*

Responsible Administrative Authority*
*Autorité administrative responsable**

Signature :
Name/nom : Dr Jitendra Kumar
Division : Administration
Date : 24 June 2016

* An official of the institution - other than the Principal Investigator - fully empowered to enter into contracting arrangements on behalf of the Institution./*Un responsable de l'institution autre que le Chercheur principal - ayant pleins pouvoirs pour passer un contrat au nom de l'institution.*

World Health Organization

WHO/SSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 5
CYBERJAYA 63000
Malaysia

WHO Reference/ *Référence OMS*

WHO Reference	2016/637886-0
Purchase Order	201522017
Reg. File	N/A
Unit Reference	MCA/MRD

TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES

GENERAL CONDITIONS

The following are the general conditions relating to this Agreement concerning WHO support for research or other technical services. The purpose of such support is to assist an Institution to undertake, for WHO, investigations on a particular problem or other work which has been agreed upon by the Institution and WHO.

1 INSTITUTION AND PRINCIPAL INVESTIGATOR
1.1 The Institution and the Principal Investigator (or Responsible Technical Officer), who must be an employee of the Institution, shall be jointly responsible for all the technical and administrative aspects of the work referred to in this Agreement.
1.2 The Institution is required to notify WHO immediately of knowledge that the Principal Investigator will cease or ceases to be an employee of the Institution or is no longer continuing the responsibilities centered by this Agreement. Under such circumstances WHO has the right to:
a. cancel this Agreement or
b. agree to continue the project under a new Principal Investigator proposed by the Institution and approved by WHO.

2. FINANCIAL ARRANGEMENTS
2.1 Payments shall be made to the bank account(s) of the Institution as specified in this Agreement and in accordance with the schedule of payments contained therein. If, after the submission of the final financial report referred to in paragraph 4.3 below, there remains an unused balance of funds with the Institution, this balance shall be due to WHO. In the event of this Agreement being cancelled under any circumstances, the Institution shall refund to WHO the balance of unencumbered funds. The funds provided under this Agreement shall be spent only in accordance with its terms.
2.2 The funds transferred to the Institution under this Agreement may not be used to meet any form of emoluments, travel costs or any other reimbursements of expenditure to a staff member of WHO.
2.3 Unless otherwise provided in this Agreement the funds may not be used to cover:
a. normal administrative and overhead expenses of the Institution;
b. cost of maintenance, repair, running or insurance of existing equipment and machinery belonging to the Institution;
c. cost of construction of new buildings or alterations and modifications of existing buildings and premises;
d. salary support of the Principal Investigator.

3. EQUIPMENT AND SUPPLIES
3.1 Unless otherwise agreed, and subject to subparagraph 3.2 below, any equipment acquired under this Agreement shall become the property of the Institution. The Institution and the Principal Investigator shall be jointly responsible for the proper safeguard, maintenance and care of all equipment acquired under this Agreement.
3.2 Notwithstanding subparagraph 3.1 above, the Institution shall transfer ownership of any equipment acquired under this Agreement to WHO, if so requested by WHO, upon termination or expiry of this Agreement. In such cases the Institution shall dispatch the equipment to any destination chosen by WHO, the cost of which will be borne by WHO.

4. REPORTS
The Institution shall submit technical and financial reports to WHO on the work as required, or at least annually, in accordance with the following provisions:
4.1 Technical reports shall be prepared by the Principal Investigator and forwarded through and countersigned by the authorized official of the Institution or its authorized representative. Each annual report shall summarize the results of the project and give in sufficient detail its positive and negative findings so that the value of the work can be assessed.
4.2 Financial reports shall be forwarded after being jointly certified by the Institution's Chief Financial Officer and the Principal Investigator, using form WHO 782. The reports must show the use of the funds provided by WHO compared with the original budget expenditure pattern agreed between the Institution and WHO.
4.3 All Financial and Technical reports are subject to audit by WHO, including examination of supporting documentation and relevant accounting entries in the Institution's books. In order to facilitate such reporting and audit, the Institution shall ensure that accurate and systematic accounts and records are kept in respect of the project. The final Technical and Financial reports must be submitted within 90 days after the expiry of this Agreement.

5. RELATIONSHIP AND RESPONSIBILITY OF PARTIES
The relationship of the Institution to WHO shall be that of an independent contractor. The employees of the Institution are not entitled to describe themselves as staff members of WHO. The Institution shall be solely responsible for the manner in which work on the project is carried out and accordingly shall assume full liability for any damage arising from research or other technical services under this Agreement. No liability shall attach to WHO, its advisers, agents or employees.

6. USE OF RESULTS, EXPLOITATION OF RIGHTS, AND PUBLICATION
6.1 The results of the project funded under this Agreement may be freely used or disclosed by either party provided that, without the consent of the other party, no use may be made for commercial purposes and confidentiality shall be maintained with respect to results that may be eligible for protection by proprietary rights. The Institution shall provide WHO with the results, in the form of relevant know-how and other information, and to the extent feasible, tangible products.
6.2 The industrial or commercial exploitation of any intellectual property rights, including the ownership of those rights arising from the project shall be designed to achieve, in so far as circumstances permit, the following objectives in the following order of priority:
a. the generic availability of the products of creative activity;
b. the availability of those products to the public health sector on preferential terms, particularly in developing countries;
c. the grant to each party of additional benefits, including royalties, account being taken of the relative value of each party's financial, intellectual and other contribution to the research.
6.3 The rights referred to in para. 6.2 shall belong to the Institution, or to the Principal Investigator if the Institution and WHO so agree. To the extent that the former do not intend to exercise them, the rights shall be promptly transferred to WHO, if it so requests. Each party shall provide the other with its full cooperation to permit the effective exercise of the rights. The party in which the corresponding rights are vested may file applications for industrial property protection, promptly furnishing copies of the applications and other patent documents to the other party. All rights other than the right to file applications shall be exercised in accordance with an agreement which shall be negotiated in good faith between the Institution and WHO.
6.4 In any publication by the Institution or the Principal Investigator relating to the results of the project, the responsibility for the direction of the work shall not be ascribed to WHO. Unless WHO advises otherwise, all publications shall include a notice indicating that the underlying investigation received financial support from WHO. Two off-prints or copies shall be sent to WHO unless another number is stipulated. WHO funds may not be used for publication costs unless specifically authorized.

7. RESEARCH INVOLVING HUMAN SUBJECTS
7.1 Ethical Aspects
It is the responsibility of the Institution and the Principal Investigator to safeguard the rights and welfare of human subjects involved in research supported in whole or in part by funds from WHO, in accordance with the appropriate national code of ethics or legislation, if any, and in the absence thereof, the Helsinki Declaration and any subsequent amendments. Such funds may be used only to support investigations where (a) the rights and welfare of the subjects involved in the research are adequately protected, (b) freely given informed consent has been obtained, (c) the balance between risk and potential benefits involved has been assessed and deemed acceptable by a panel of independent experts appointed by the Institution and (d) any special national requirements have been met.
7.2 Regulatory Requirements
It is the responsibility of the Institution and the Principal Investigator to comply with the relevant national regulations pertaining to research involving human subjects.
7.3 Protection of Subjects
Without prejudice to obligations under applicable laws, the Institution shall make appropriate arrangements to eliminate or mitigate the consequences to subjects or their families in the case of death, injury or illness resulting from the conduct of research referred to in paragraph 7.1. Such arrangements shall, to the extent feasible, include medical treatment and financial relief. The Institution and Principal Investigator undertake to protect the confidentiality of the information relating to the possible identification of subjects involved in the research involving human subjects conducted under the auspices of this Agreement.

8. RESEARCH INVOLVING THE USE OF LABORATORY ANIMALS
The Institution undertakes that living vertebrate animals required for use as laboratory animals for the research to be carried out under this Agreement, shall be handled in accordance with generally accepted principles for the humane treatment of such animals and the avoidance of unnecessary suffering.

9. RESEARCH SAFETY
It is the responsibility of the Institution to establish and implement policies and practices to assure and provide for the safety of its employees, the public, and the environment during the conduct of the supported research. If the supported research involves the use of dangerous biological agents, the Institution shall establish and implement an appropriate safety plan.

10. PUBLICITY
The Institution and the Principal Investigator shall not refer to the relationship of WHO to the project, or to products or processes connected with the project, in any statement or material of a publicity or promotional nature issued for commercial purposes, or with a view to financial benefit.

11. SETTLEMENT OF DISPUTES
Any matter relating to the interpretation or application of this Agreement which is not covered by its terms shall be resolved by reference to Swiss law. Any dispute relating to the interpretation or application of this Agreement shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the Rules of Arbitration of the International Chamber of Commerce. The parties shall accept the arbitral award as final.

12. PRIVILEGES AND IMMUNITIES
Nothing contained in or relating to this Agreement shall be deemed to constitute a waiver of any of the privileges and immunities enjoyed by WHO and/or as submitting WHO to the national court jurisdiction.

World Health Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ *Référence OMS*	
WHO Reference	2016/637886-0
Purchase Order	201522017
Reg. File	N/A
Unit Reference	MCA/MRD

TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES

CONDITIONS GENERALES

Les conditions générales énoncées ci-après s'appliquent au présent Accord sur l'appui de l'OMS aux recherches ou autres services techniques. Cet appui vise à aider une institution à entreprendre pour le compte de l'OMS des investigations portant sur un problème particulier ou des travaux convenus entre l'Institution et l'OMS.

1. INSTITUTION ET CHERCHEUR PRINCIPAL
1.1 L'Institution et le Chercheur principal (ou l'Administrateur technique responsable), lequel doit être employé par l'Institution, sont conjointement responsables de l'ensemble des aspects techniques et administratifs des travaux visés par le présent Accord.
1.2 L'Institution est tenue d'aviser immédiatement l'OMS lorsqu'elle apprend que le Chercheur principal va cesser, ou a cessé, d'être employé par elle, ou bien qu'il ne continue pas à exercer les fonctions visées par le présent Accord. En pareil cas, l'OMS peut:
a. soit annuler le présent Accord;
b. soit accepter de poursuivre le projet sous la conduite d'un nouveau Chercheur principal proposé par l'Institution et approuvé par l'OMS.

2. DISPOSITIONS FINANCIERES
2.1 Des versements seront faits au(x) compte(s) bancaire(s) de l'Institution comme il est stipulé dans le présent Accord et conformément au calendrier qui y figure. Si, après communication du rapport financier final mentionné plus loin au paragraphe 4.3, il apparaît que l'Institution détient un solde non utilisé, ce solde reste payable à l'OMS. En cas d'annulation du présent Accord, quelles qu'en soient les circonstances, l'Institution restituera à l'OMS les sommes non encore engagées. Les sommes fournies en vertu du présent Accord ne peuvent être dépensées que conformément aux dispositions dudit Accord.
2.2 Les fonds versés à l'Institution en vertu du présent Accord ne peuvent être utilisés pour verser des émoluments quelconques à un fonctionnaire de l'OMS, couvrir ses frais de voyage ou lui rembourser toute autre dépense.
2.3 Sauf dispositions contraires du présent Accord, ces fonds ne peuvent être utilisés pour couvrir:
a. les dépenses administratives et les frais généraux normaux de l'Institution;
b. le coût de l'entretien, de la réparation, de l'exploitation ou de l'assurance de matériels ou d'appareils existants qui appartiennent à l'Institution;
c. le coût de la construction de nouveaux bâtiments, ou de la transformation ou de la modification de bâtiments et locaux existants;
d. le versement d'un complément de traitement au Chercheur principal.

3. MATERIEL ET FOURNITURES
3.1 Sauf convention contraire, et sous réserve des dispositions de l'article 3.2 ci-après, tout matériel obtenu en vertu du présent Accord sera la propriété de l'Institution. L'Institution et le Chercheur principal seront conjointement responsables du bon état de conservation et d'entretien de tout matériel acquis en application du présent Accord.
3.2 Nonobstant les dispositions de l'article 3.1 ci-dessus et si l'OMS en fait la demande, l'Institution transférera à celle-ci, lors de la résiliation ou de l'expiration du présent Accord les droits de propriété afférents à tout matériel acquis au titre dudit Accord. L'Institution expédiera alors ce matériel vers toute destination que lui aura indiquée l'OMS, les frais d'expédition étant à la charge de cette dernière.

4. RAPPORTS
L'Institution soumettra à l'OMS des rapports techniques et financiers concernant ses travaux, chaque fois qu'il y a lieu et au moins une fois par an, selon les modalités suivantes.
4.1 Les rapports techniques seront établis par le Chercheur principal, envoyés sous couvert du responsable de l'Institution ou de son représentant l'un et l'autre dûment autorisés, et contresignés par eux. Chaque rapport devra résumer les résultats du projet et en exposer les conclusions positives ou négatives de façon assez détaillée pour permettre d'apprécier la valeur des travaux.
4.2 Les rapports financiers devront être envoyés, après avoir été visés conjointement par le Chef des Services financiers de l'Institution et par le Chercheur principal qui utiliseront à cette fin la formule WHO 162. Les rapports devront indiquer l'utilisation des fonds provenant de l'OMS au regard des prévisions de dépenses initiales dont il aura été convenu entre l'Institution et l'OMS.
4.3 Tous les rapports financiers et techniques sont soumis par l'OMS à une vérification comprenant l'examen de toutes pièces justificatives ainsi que des écritures comptables correspondantes dans les livres de l'Institution. En vue de faciliter l'établissement et la vérification de ces rapports, l'Institution veillera à la tenue de comptes et de registres exacts et systématiques pour tout ce qui concerne le projet. Les rapports techniques et financiers finaux devront être présentés dans les 90 jours suivant l'expiration du présent Accord.

5. RELATIONS ENTRE LES PARTIES ET LEURS RESPONSABILITES
L'Institution agira à l'égard de l'OMS en tant qu'entrepreneur indépendant: ses employés ne pourront se prévaloir de la qualité de membres du personnel de l'OMS. L'Institution sera seule responsable de la façon dont s'exécute le projet et, partant, assumera l'entière responsabilité de tout dommage résultant des recherches ou d'autres services techniques visés par le présent Accord. Aucune responsabilité ne pourra incomber à l'OMS, ses conseillers, agents ou employés.

6. UTILISATION DES RESULTATS, EXPLOITATION DES DROITS, ET PUBLICATION
6.1 Les résultats du projet financé en vertu du présent Accord pourront être librement utilisés ou divulgués par l'une ou l'autre partie. Toutefois, à défaut de l'assentiment de l'autre partie, les résultats ne pourront être utilisés à des fins commerciales et, s'ils sont susceptibles d'être protégés par des droits de propriété, ils conserveront leur caractère strictement confidentiel. L'Institution transmettra à l'OMS les résultats des recherches, sous forme de savoir-faire et autres intellectuels, y compris les droits qui s'attachent au savoir-faire, découvert au projet, deux parmi elles, dans toute la mesure du possible, d'atteindre les objectifs suivants énoncés par ordre de priorité:
a. mise à la disposition de tous les produits de l'activité créatrice;
b. leur mise à la disposition du secteur de la santé publique, notamment dans les pays en développement à des conditions préférentielles;
c. octroi à chaque partie d'avantages additionnels, y compris sous formes de redevances, compte tenu de la valeur relative de ses contributions financières, intellectuelles et autres.
6.3 Les droits mentionnés plus haut au paragraphe 6.2 seront la propriété de l'Institution, ou du Chercheur principal et l'Institution et l'OMS en conviennent ainsi. Dans la mesure où l'Institution n'entend pas les exercer, les droits seront promptement transmis à l'OMS, si celle-ci le demande. Chaque partie coopérera pleinement avec l'autre pour lui permettre d'exercer effectivement ses droits. La partie détentrice des droits pourra déposer des demandes de propriété industrielle et devra alors remettre à l'autre partie copie de ces dépôts et des autres documents relatifs au brevet. Tous les droits autres que celui de déposer des demandes s'exerceront aux termes d'un accord qui sera négocié de bonne foi entre l'Institution et l'OMS.
6.4 Dans aucune de ses publications concernant les résultats du projet, l'Institution ou le Chercheur principal n'attribuera à l'OMS la responsabilité de la direction des travaux. Sauf instructions contraires de l'OMS, toutes les publications comporteront une note indiquant que les recherches qui sont à l'origine des résultats ont reçu un appui financier de l'OMS. A moins qu'un autre chiffre n'ait été stipulé, deux exemplaires ou tirés à part de ces publications seront envoyés à l'OMS et, sauf autorisation expresse, les fonds de l'OMS ne pourront être utilisés pour couvrir les coûts de publication.

7. RECHERCHES IMPLIQUANT L'ETUDE DE SUJETS HUMAINS
7.1 Aspects déontologiques
Il incombe à l'Institution et au Chercheur principal de s'assurer qu'au cours des travaux financés totalement ou en partie par l'OMS et impliquant l'étude de sujets humains, les droits et la santé de ces derniers soient protégés conformément au code de déontologie ou à la législation du pays ou, à défaut, à la Déclaration d'Helsinki et aux amendements qui pourraient lui être ultérieurement apportés. Les fonds ne peuvent être utilisés pour financer des recherches que si les conditions suivantes sont remplies:
a. les droits et le bien-être des sujets impliqués sont suffisamment protégés;
b. le consentement libre et éclairé des intéressés a été obtenu;
c. des experts indépendants désignés par l'Institution ont pesé les risques et les avantages potentiels et ont jugé qu'ils s'équilibraient de manière acceptable, et
d. il a été satisfait à toute exigence particulière de la réglementation nationale.
7.2 Dispositions réglementaires
Il incombe à l'Institution et au Chercheur principal de respecter la réglementation nationale relative aux recherches impliquant l'étude de sujets humains.
7.3 Protection des sujets d'expérience
Sans préjudice des obligations qui lui incombent aux termes des lois en vigueur, l'Institution prendra des mesures appropriées en vue d'éliminer ou d'atténuer les conséquences des expériences pour les sujets ou leur famille en cas de décès, de traumatisme ou de maladie résultant de la conduite des recherches mentionnées au paragraphe 7.1. Ces mesures comprendront, dans la mesure du possible, un traitement médical et un dédommagement financier. L'Institution et le Chercheur principal s'engagent à protéger le caractère confidentiel des informations qui pourraient permettre d'identifier les sujets impliqués dans les études effectuées en vertu du présent Accord.

8. RECHERCHES IMPLIQUANT L'UTILISATION D'ANIMAUX DE LABORATOIRE
L'Institution s'engage à veiller à ce que les animaux vertébrés vivants qu'il sera nécessaire d'utiliser comme animaux de laboratoire pour des recherches entreprises en vertu du présent Accord soient traités conformément aux principes universellement reconnus qui veulent que l'on épargne à ces animaux toute souffrance inutile.

9. SECURITE DES RECHERCHES
Il incombe à l'Institution d'arrêter et d'appliquer des politiques et pratiques prouvant et garantissant la sécurité de ses employés et du public ainsi que celle de l'environnement pendant les recherches soutenues par l'OMS. Si les travaux impliquent l'utilisation de substances biologiques dangereuses, l'Institution établira et appliquera un plan de sécurité approprié.

10. PUBLICITE
L'Institution et le Chercheur principal ne pourront faire mention, dans un quelconque écrit ou déclaration à caractère publicitaire ou promotionnel diffusé à des fins commerciales, ou en vue d'un avantage financier, du lien existant entre l'OMS et le projet ou les produits ou procédés en découlant.

11. REGLEMENT DES LITIGES
Toute question concernant l'application ou l'interprétation du présent Accord que les dispositions de ce dernier ne permettent pas de résoudre doit être résolue par référence au droit suisse. Tout différend relatif à l'application ou à l'interprétation du présent Accord qui n'aurait pu être résolu à l'amiable, fera l'objet d'une conciliation. En cas d'échec de celle-ci, le différend sera réglé par arbitrage. Les modalités de l'arbitrage seront convenues entre les parties ou, en absence d'accord, seront déterminées selon le règlement d'arbitrage de la Chambre de Commerce Internationale. Les parties accepteront que la sentence arbitrale sera finale.

12. PRIVILEGES ET IMMUNITES
Aucun des termes du présent Accord ne sera considéré comme constituant une

World Health Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ *Référence OMS*	
WHO Reference	2016/637888-0
Purchase Order	201522017
Reg. File	N/A
Unit Reference	MCA/MRD

TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES

informations pertinentes et, dans la mesure du possible, lui fournira des produits concernés.
6.2 L'exploitation industrielle ou commerciale de tout droit de propriété

renonciation à quelque privilège ou immunité que ce soit dont jouit l'OMS et/ou comme constituant une soumission de l'OMS à la compétence d'un quelconque tribunal national.

Registrar
Swami Vivekanand
Subharti University
MEERUT

CLINICAL STUDY AGREEMENT

CLINICAL STUDY AGREEMENT BETWEEN THE SPONSOR, CADILA HEALTHCARE LIMITED, ZYDUS TOWERS, SATELLITE CROSS ROADS, AHMEDABAD-380015, INDIA and

Dr. Abhishek Gupta, Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005
And

Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005

Project : **RABIMAMBs**
Protocol No.: **RABIMABs.16.001.01**

This Clinical Study Agreement ("Agreement") between

1. CADILA HEALTHCARE LIMITED, ZYDUS TOWERS, SATELLITE CROSS ROADS, AHMEDABAD-380015, INDIA (HEREAFTER REFERED AS "THE SPONSOR") AND
2. Dr. Abhishek Gupta, Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005, and
3. Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005

When signed by all parties, is effective from the last signature date

THE SPONSOR wishes to sponsor a clinical study entitled "Randomized, multi-centric, open-label, comparator-controlled study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for post-exposure prophylaxis in patients following potential rabies exposure"., Centre Subharti Medical College, Meerut to be conducted at Institution. This agreement also covers any companion protocol(s), later developed and approved by both/three parties, that are conducted concurrently with the protocol identified above (collectively, "Protocol") and that involve some or all of the same subjects (collectively, "Study"). The sponsor hereby declares that all the necessary permissions and licenses required under the provision of relevant acts and rules namely Drug & Cosmetics Act and Drug & Cosmetic Rules 1945 and their subsequent amendments (including Schedule Y) are obtained by them for the use of the same on the study subjects.

THE PARTIES AGREE AS FOLLOWS

1. The sponsor would like to test the drug namely RABIMABs which will be used in patients suffering from Rabies. The sponsor hereby declares that all the necessary permissions and licenses required under the provision of relevant acts and rules namely Drug & Cosmetics Act and Drug & Cosmetic Rules 1945 and their subsequent amendments (including Schedule Y) are obtained by them for the use of the same on the study subjects.
2. The sponsor have approached the investigator as they desire to perform the study in regards to the said drug in accordance with the applicable guidelines on Good Clinical Practice, ethics and local regulations.
   The Principal Investigator hereby confirms that he has read and understood the Clinical Trail protocol entitled "Randomized, multi-centric, open-label, comparator-controlled study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for post-exposure prophylaxis in patients following potential rabies exposure".
3. All amendments and appendices have also been read and understood. The investigator agrees to the protocol Randomized, multi-centric, open-label, comparator-controlled study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for post-exposure prophylaxis in patients following potential rabies exposure".
   and will perform the study in accordance with the applicable guidelines on Good Clinical Practice, ethics and local regulations.
3. Investigators and Research Staff.
3.1. Principal Investigator. The Study will be conducted by Dr. Abhishek Gupta (HEREAFTER REFERED AS "PRINCIPAL INVESTIGATOR") at Subharti Medical College, Subhartipuram, NH58, Delhi-Haridwar Bypass road, Meerut. The term "Investigator" as used in this Agreement refers, as applicable, to the Principal Investigator, subinvestigators, research staff or the Institution or all or any of them.
3.2. Subinvestigators and Research Staff. Investigator will ensure that only individuals, who are appropriately trained and qualified, assist in the conduct of the Study as subinvestigators or research staff.
3.3. Obligations. Institution will ensure that all personnel, who assist in the conduct of the Study, are informed of and agree to abide by all terms of this Agreement applicable to the activities they perform. Institution is responsible to THE SPONSOR for compliance by all Study personnel, including THE PRINCIPAL INVESTIGATOR, with the terms of this Agreement.
3.4. No Substitution. Institution shall not reassign the conduct of the Study to a different Principal Investigator without prior written authorization from THE SPONSOR.
3.5. Delegation of Duties by Principal Investigator. Principal Investigator may delegate duties and responsibilities to subinvestigators or research staff only to the extent permitted by the relevant laws and regulations governing the conduct of clinical investigations in India.
3.6. Compliance with Institutional Policies. Principal Investigator will comply with the policies and procedures of the organization(s) with which Principal Investigator is affiliated, including any applicable financial policies. Principal Investigator will notify THE SPONSOR promptly of any conflict between the terms of this Agreement and any such policy or procedure, and the parties will attempt to reach an appropriate accommodation.
4. Funding. THE SPONSOR will provide mutually agreed upon funding in support of this Study as set out in Attachment A and subject to the terms specified in that Attachment.
5. Protocol. Investigator will conduct the Study in accordance with the Protocol, ICH GCP guidelines and applicable rules and regulations in India.
5.1. Amendments. The Protocol may be modified only by a written Amendment, signed by both THE SPONSOR and THE PRINCIPAL INVESTIGATOR.
5.2. Emergency Amendments. If it is necessary to change the Protocol on an emergency basis for the safety of the subjects, Investigator will notify THE SPONSOR and the responsible Independent Ethics Committee or Institutional Review Board (as applicable) as soon as practicable but, in any event, not later than five working days after the change is implemented. Any emergency change to the Protocol must be followed by a written Amendment.
5.3. No Additional Research. No additional research may be conducted on Study subjects during the conduct of the Study unless it is approved and documented as a sub-study protocol or an Amendment to the original Protocol. Such prohibited research activities include, but are not limited to, analyses of biological samples from Study subjects for any non-therapeutic purpose.
6. Subject Enrollment. Investigator has agreed to enroll in Study a minimum of 20 subjects by 3 months unless THE SPONSOR extends this enrollment period by written notification. A qualified subject is one who meets all Protocol criteria such as d
7. inclusion & exclusion criteria and agrees to participate in the study through informed consent in writing.
7.1. Excess Enrollment. If investigator enrolls the maximum number of qualified subjects before the deadline, THE SPONSOR may or may not invite Investigator to enroll additional subjects. However, The Institution and/or THE PRINCIPAL INVESTIGATOR shall not enroll more than 50 subjects without prior approval by THE SPONSOR.

7.2. Failure to Enroll. If Investigator fails to enroll subjects at a rate adequate to meet the enrollment requirement, THE SPONSOR shall be free to terminate the Study early (see Section 25, Termination).

8. Study Conduct. Investigator will conduct Study in accordance with the Protocol, THE SPONSOR's written instructions, International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines and all applicable governmental laws, rules, and regulations.

8.1. No Charge for Investigational Drug or Reimbursed Services. Investigator will not charge a Study subject or third-party payer for Investigational Drug (see Section 13, Investigational Drug) or for any services reimbursed by THE SPONSOR under this Agreement.

9. Independent Ethics Committee/Institutional Review Board. Before the Study is initiated, Investigator will ensure that both the Study and the informed consent form are approved by an Independent Ethics Committee or Institutional Review Board (as applicable)(both referred to as a 'IRB') that complies with all applicable laws and regulations. Investigator will further ensure that the Study is subject to continuing oversight by the IRB throughout its conduct.

9.1. Study Disapproval. If, through no fault of Investigator, the Study is disapproved by the IRB, this Agreement will immediately terminate with no penalty to the Investigator, as provided in Section 25.1a, Disapproval by IRB, below.

10. Data Protection. Data collected in Study may include personal data and sensitive personal data which is subject to specific legislation relating to the processing, storage, transfer and use of such data Investigator will comply with all relevant laws relating to the protection and use of personal data and data privacy in its conduct and reporting of the Study. The Investigator shall take all technical and organizational measures to prevent unauthorized or unlawful processing or accidental loss or destruction of, or damage to, or disclosure of such data. THE SPONSOR will take appropriate measures to protect the confidentiality and security of all personal data that it receives from Investigator in connection with the Study. Personal data relating to the Investigator shall be processed and used for the purposes of administration of this agreement and in connection with the Study and will be held on one or more databases for the purposes of determining the Investigator's involvement in future research and in order to comply with any regulatory requirements. Such data may be disclosed or transferred to other members of Cadila Healthcare Limited group of companies, to representatives and contractors working on behalf of THE SPONSOR group and to regulatory authorities across the world. The Investigator shall ensure that all necessary consents are in place to comply with the provisions of this clause.

11. Informed Consent and Authorization to Use and Disclose Health Information

11.1. Informed Consent: Investigator will provide THE SPONSOR an opportunity to review and approve the content of the informed consent form (including any revisions made during the course of the Study) before it is used. Investigator will obtain a written informed consent from each Study subject and will maintain a signed original of that consent in the subject's record. Investigator will allow THE SPONSOR to inspect signed informed consent forms or photocopies there of during monitoring visits or audits (see Monitoring and Audits, Section 17).

12. Adverse Events. Investigator will report adverse events experienced by Study subjects in accordance with instructions in the Protocol and applicable regulations. This includes, where required, prompt reporting by telephone or facsimile. THE SPONSOR shall, so far as is lawful, have full responsibility for the reporting of all adverse events to local and international regulatory and/or health authorities.

13. Investigational Drug. THE SPONSOR will provide Investigator with sufficient quantities of the investigational drug(s) needed to conduct the study.

13.1. Custody and Dispensing THE PRINCIPAL INVESTIGATOR will maintain appropriate control of supplies of Investigational Drug and will not provide it to anyone else except subinvestigators or research staff. THE PRINCIPAL INVESTIGATOR shall maintain the records of inventory of the Investigational drug.

13.2. Use. Investigator will use Investigational Drug only as specified in the Protocol. Any other use of Investigational Drug constitutes a material breach of this Agreement.

13.3. Ownership of Investigational drug. Investigational drug and remains the property of THE SPONSOR except for, and limited to, the use specified in the Protocol. THE SPONSOR grants Investigator no express or implied intellectual property rights in Investigational drug or in any methods of making or using Investigational drug.

14. Equipment. The SPONSOR may provide certain equipment for use by the Investigator during the conduct of the study ("Equipment").

14.1. Ownership and Use. Equipment is and remains the property of THE SPONSOR and INVESTIGATOR may use Equipment only for purposes of the study.

14.2. Investigator Responsibilities. Investigator will comply with any operating and maintenance instructions provided by THE SPONSOR or the manufacturer and will store Equipment under conditions that are appropriate to the nature f the Equipment and that minimize the risk of loss or damage.

14.3. Liability. THE SPONSOR has no liability for damages of any sort, including personal injury or property damage, resulting from the use of Equipment except to the extent that such damages were caused by negligence or willful misconduct of THE SPONSOR.

15. Confidential Information. During the course of the Study, Investigator may receive or generate information that is confidential to THE SPONSOR

15.1. Definition. Except as specified in Section 15.2, Exclusions, below, "Confidential Information" includes

a. the Protocol,
b. the Investigator Brochure,
c. Study Data (as defined in Section 16, Study Data, Biological Samples, and Study Records, below), subject to Investigator's right to publish the results of the Study (as described in Section 19, Publications, below),
d. Biological Sample Analysis Data (as defined in Section 15, Study Data, Biological Samples, and Study Records, below).
e. Any other information related to the study, the investigator drug or Sponsor technology, research or business plans that sponsor provides to the investigator in writing or other tangible form and marks as CONFIDENTIAL or initially discloses orally and then summarize and confirms in writing as CONFIDENTIAL within 90 days after the date of oral disclosure.

15.2. Exclusions. Confidential Information does not include information that (i) is known or open to the public or otherwise in the public domain at the time of disclosure or (ii) becomes part of the public domain during the term of this confidentiality obligation by any means other than breach of this Agreement by Investigator (iii) is already known to Investigator at the time of disclosure and is free of any obligations of confidentiality, or (iv)is obtained by Investigator, free of any obligations of confidentiality, from a third party that has a lawful right to disclose it.

15.3. Obligations of Confidentiality. Unless THE SPONSOR provides prior written consent, Investigator may not use Confidential Information for any purpose other than that authorized in this Agreement, nor may Investigator and or Institute disclose Confidential Information to any third party except as authorized in this Agreement or as required by law.

a. Required disclosure of Confidential Information to the IRB or to regulatory representatives is specifically authorized.
b. Publication of the results of the Study based on Study Data collected or generated by Investigator is specifically authorized, of this Agreement.

15.4. Disclosure Required by Law. If disclosure of Confidential Information to any party other than the Independent Ethics Committee, relevant regulatory authority is required by law, that disclosure does not constitute a breach of this Agreement so long as Investigator

a. notifies THE SPONSOR in writing in 15 working days advance of the disclosure so as to allow THE SPONSOR to take legal action to protect its Confidential Information,
b. discloses only that Confidential Information required to comply with the legal requirement, and
c. continues to maintain the confidentiality of this Confidential Information with respect to all other third parties.

15.5. Individually Identifiable Health Information. If, in connection with this Study or performance of this Agreement, THE SPONSOR comes into contact with individuality identifiable health information relating to subjects who are not Study subjects, THE SPONSOR agrees to maintain the confidentiality of such information and not to use it for any purpose.

15.6 Survival of Obligations. These obligations of confidentiality survive termination of this Agreement and continue for a period of five years after completion of the study or termination, which ever is earlier.

15.7 Return of Confidential Information. If requested by THE SPONSOR in writing, Investigator will return all Confidential Information except that required to be retained at the Study site by law. However, Investigator may retain a single archival copy of the Confidential Information for the sole purpose of determining the scope of obligations incurred under this Agreement.

16. Study Data, Biological Samples and Study Records.

16.1 Study Data. During the course of the Study, Investigator will collect and submit certain data to THE SPONSOR or its agent, as specified in the Protocol. This may include case report forms or their equivalent ("Case Report Forms"), or other types of medical images, ECG, or other types of tracings or printouts, data summaries, or any combination of these (collectively, "Study Data"). Investigator will ensure accurate and timely collection, recording, and submission of Study Data. Investigator will deliver Study Data to THE SPONSOR or its agent within the time periods specified below:

a. Ownership of Study Data. Subject to Investigator's right to publish the results of the Study (see Section 19, Publications), THE SPONSOR is the exclusive owner of all Study Data.

b. Non-exclusive License. THE SPONSOR grants Institution a royalty free non-exclusive license, with no right to sublicense, to use Study Data (not related with the investigator drug) for internal research or educational purposes.

c. Data Management and statistical Analysis. THE SPONSOR or its representative shall carry out the data management and statistical analysis. THE SPONSOR may consult and / or provide THE PRINCIPAL INVESTIGATOR for interpretation during report writing.

d. THE SPONSOR is the exclusive owner of study data.

16.2 Biological Samples. If so specified in the Protocol, Investigator may collect and provide to THE SPONSOR or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Study subjects for testing that is directly related to subject care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing ("Biological Samples").

a. Use. Investigator will not use Biological Samples collected under the Protocol in any manner or for any purpose other than that described in the Protocol.

b. Analysis samples. THE SPONSOR or its designees will test Biological Samples as described in the Protocol. Unless otherwise specified in the Protocol, THE SPONSOR will provide the results of these tests ("Biological Sample Analysis Data") to the Investigator or Study subject.

c. Ownership. THE SPONSOR is the exclusive owner of all Biological Samples and Biological Sample Analysis Data.

16.3 Study Records. Investigator will ensure that subject's Study records, which include the Investigator's copies of all Study Data as well as relevant source documents (collectively, "Study Records"), are kept up to date and maintained in accordance with applicable regulations and institutional guidelines.

a. Retention. Investigator will retain Study Records, under storage conditions conducive to their stability and protection, for a period of 15 years after termination of the Study unless THE SPONSOR authorizes, in writing, earlier destruction. Investigator agrees to notify THE SPONSOR before destroying any Study Records after the required retention period. Investigator further agrees to permit THE SPONSOR to ensure that the records are retained for a longer period if necessary, at THE SPONSOR expense, under an arrangement that protects the confidentiality of the records (e.g., secure off-site storage).

17. Monitoring, Inspections and Audits.

17.1 Monitoring. THE SPONSOR shall be entitled at its absolute discretion (and in such form as THE SPONSOR sees fit) to monitor and audit the conduct of the Study. Upon reasonable notice, Institution will permit THE SPONSOR representatives access to the premises, facilities, procedures and records relating to the Study, investigators, and research staff as required to accomplish this. The Institution agrees to co-operate and provide all reasonable assistance with any monitoring and/or auditing activity. No such monitoring and/or auditing by THE SPONSOR will relieve the Investigator of any of its obligations hereunder.

17.2 Inspections and Audits. The Study is subject to inspection by regulatory agencies worldwide. Regulatory inspections may occur after completion of the Study and may include auditing of Study Records. Auditing involves comparison of Case Report Forms or Data Records with the source documentation on which they are based. THE SPONSOR may also choose to audit Study Records as part of its monitoring of Study conduct.

a. Notification. Investigator will notify THE SPONSOR as soon as reasonably possible if the site is inspected or scheduled to be inspected by a regulatory agency.

b. Cooperation. Investigator will cooperate with regulatory agency or THE SPONSOR representatives in the conduct of inspections and audits and will ensure that Study Records are maintained in a way that facilitates such activities.

c. Resolution of Discrepancies. Investigator will promptly resolve any discrepancies that are identified between the Study Case Report Forms and the subject's medical records.

d. Inspection Findings and Responses. Investigator will promptly forward to THE SPONSOR copies of any inspection findings that Investigator receives from a regulatory, agency. Whenever feasible, Investigator will also provide THE SPONSOR with an opportunity to prospectively review and comment on any Investigator responses to regulatory agency inspections.

e. Data Clarification Form: THE SPONSOR may raise data clarification forms (queries) during or after the monitoring and/or auditing and/or statistical review of the study, which THE INSTITUTION OR THE PRINCIPAL INVESTIGATOR shall clarify within 7 working days.

f. Study Conduct Evaluations. THE SPONSOR or its external service providers may document and evaluate the performance of Investigator in the conduct of the Study. THE SPONSOR will use these evaluations solely for internal purposes.

18. Inventions.

18.1 Notification. If the conduct of Study results in any invention or discovery whether patentable or not ("Invention"), Investigator will promptly inform THE SPONSOR.

18.2 Assignment. Investigator will assign all interest in any such Invention to THE SPONSOR, free of any obligation or consideration beyond that provided for in this Agreement.

18.3 Assistance. Investigator will provide reasonable assistance to THE SPONSOR in filing and prosecuting any patent applications relating to Invention, at THE SPONSOR's expense.

19. Publications.

19.1 Prepublication Review. THE SPONSOR has no objection to publication by Investigator of any information collected or generated by Investigator, whether or not the results are favorable to the Investigational Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Investigator will provide THE SPONSOR an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed. The timing of such publication shall be mutually agreed upon.

a. Submission to THE SPONSOR: Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to THE SPONSOR at least 90 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 360 days.

b. Redaction of Confidential Information. Investigator will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.

20. Indemnification. THE SPONSOR will provide an indemnity to the Institution in respect of the Study (Annexure B).

21. Debarment and Exclusion. Institution and Principal Investigator each certify that it/s/he is not debarred and that it/s/he is not and will not use in any capacity the services of any person debarred under such law with respect to services to be performed under this Agreement. During the term of this Agreement and for three years after its termination, Institution and Principal Investigator will notify THE SPONSOR promptly if either of these certifications needs to be amended in light of new information.

22. Use of Name. Neither party will use the name of the other party or any of its employees for promotional or advertising purposes without written permission from the other party. However, THE SPONSOR reserves the right to identify THE PRINCIPAL INVESTIGATOR and Institution in association with a listing of the Protocol in publicly available listings of ongoing clinical trials, or other subject recruitment services or mechanisms.

23. Assignment and Delegation.

23.1 Institution may not assign its rights or delegate or subcontract any duties under this Agreement without written permission from THE

CMS DISBURSEMENT CHEQUE
VALID FOR THREE MONTHS FROM THE DATE OF ISSUE

2 9 1 1 2 0 1 7

OR ORDER/आदेश अनुसार

M.K.B.Charitable Trust

ELEVEN THOUSAND FOUR HUNDRED NINETY ONLY **

अदा करें ₹ ******11,490.00

FOR CADILA HEALTHCARE LIMITED

Authorised Signatory

A/C No 00060310000747

PAYABLE AT ALL CLEARING BRANCHES OF HDFC BANK LTD

⑈158983⑈ 380240002⑆ 901066⑈ 30

Registrer
Swami Vivekanand
Subharti University
MEERUT

World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 4447
Fax direct: +41 22 791 4385
E-mail : simonjo@who.int

In reply please refer to:

Your reference: MCA-PO 201522017

Dr Sunil Sawazal
Center for Public Health Kinetics
214-A Basement
Vinoba Puri,
Lajpat Nagar
India

03 July 2017

Dear Dr Sawazal,

No cost extension to the first year Technical Services Agreement (TSA) with The Center for Public Health Kinetics India

This is with reference to your e-mail of 14 June 2017 requesting an extension to the Technical Services Agreement for the first year of the project entitled "Establishing the optimal dose of therapeutic zinc supplementation for the treatment of acute diarrhea in under five children - a dose response trial in a South Asian and a Sub-Saharan African setting (ZTDT)-Tanzania study", covering the period of 15 June 2016 to 14 June 2017.

We hereby confirm that WHO agrees to a no-cost extension to the above-mentioned TSA until 31 December 2017.

The detailed statement of work to be performed is contained in the aforementioned TSA, and the work will be performed in accordance with the terms and conditions contained therein, except as modified by this letter. If you agree with the foregoing, please would you sign and date both originals of this letter and return one original to us for our records.

Yours sincerely,

Dr Anthony Costello
Director
Department of Maternal, Newborn, Child and Adolescent Health

I agree to the terms and conditions of the above.

Dr Sunil Sawazal — Date: July 14, 2017

ORIENTAL BANK OF COMMERCE
SUBHARTI KKB CHARIT. TRUST

Customer Account Ledger Report from 01-04-2017 to 22-05-2018

Page 96
AJ160355 5228

Account No : 52280211017748
ADDRESS : BAMRAT PLACE
GARH ROAD
MEERUT
UTTAR PRADESH
250001
INDIA

INR SWAMI VIVEKANAND SUBHARTI UNIVERSITY (GENERAL FUND)

DATE : 22-05-2018 12:07:48

B/F Balance : 25,22,728.77Cr

Order by transaction Date.

Tran Date	Particulars	Cheque No.	Dr. Amount (INR)	Cr. Amount (INR)	Balance
20-02-2018	NEFT-CR/SAA53182962/TUSHAR	540419	9,330.60		25,13,398.77Cr
20-02-2018	NEFT-CR/SAA53182800/LALIT K	540418	2,500.00		25,10,898.77Cr
20-02-2018	NEFT-CR/SAA53183141/MOHD SA	540436	2,000.00		25,08,898.77Cr
21-02-2018	NEFT-AASHU KUMAR			3,502.00	25,12,400.77Cr
21-02-2018	By Inst.418537/SBI/			7,000.00	25,19,400.77Cr
21-02-2018	DILIP KUMAR TRANSFER TXN	540705	8,764.00		25,10,636.77Cr
21-02-2018	Meenakshi Sharma	540693	2,000.00		25,08,636.77Cr
21-02-2018	KANIKA MUNESH TRANSFER TXN	540899	53,526.00		24,55,110.77Cr
21-02-2018	KRITIKA JAINTRANSFER TXN	540900	1,13,395.00		23,41,715.77Cr
21-02-2018	RICHA RAI TRANSFER TXN	540898	56,921.00		22,84,794.77Cr
21-02-2018	NEFT-RAJEEV KUMAR RAJPAI			32,000.00	23,16,794.77Cr
22-02-2018	NEFT-NEW TYRES HOUSE	540689		35,000.00	23,51,794.77Cr
22-02-2018	ISHEETA MANCHANDA	540453	78,333.00		22,73,461.77Cr
22-02-2018	NORCUSTOMER INTERBRANC	540699	4,063.00		22,69,398.77Cr
23-02-2018	JALBD-REENA	540734	2,000.00		22,67,398.77Cr
23-02-2018	KAPIL KUMAR	279732	5,000.00		22,62,398.77Cr
23-02-2018	SHALU SHARMA DO SUBHASH	540907	2,000.00		22,60,398.77Cr
23-02-2018	GEETIKA NAIN TRANSFER TXN	540904	20,429.00		22,39,969.77Cr
23-02-2018	YAMINI VERMA TRANSFER TXN	540906	57,291.00		21,82,678.77Cr
23-02-2018	TONIKA GUPTA TRANSFER TXN	540905	56,791.00		21,25,887.77Cr
23-02-2018	NAVROOP KUMAR TRANSFER TXN	540746	57,391.00		20,68,496.77Cr
26-02-2018	MOHIT KUMAR	540437	5,000.00		20,63,496.77Cr
26-02-2018	kaus		3,090.00		20,60,406.77Cr
26-02-2018	SHALINI TIWARI 040446			75,000.00	21,35,406.77Cr
26-02-2018	SHALINI TIWARI 040447			10,000.00	21,45,406.77Cr
26-02-2018	SAIBULNISHA 320546	540916		15,000.00	21,60,406.77Cr
26-02-2018	KAMAN BANSAL TRANSFER TXN	540914	55,023.00		21,05,383.77Cr
26-02-2018	ABHINAV TRANSFER TXN	540915	52,411.00		20,52,972.77Cr
26-02-2018	NIMISHA GUPTA TRANSFER TXN	540885	57,021.00		19,95,951.77Cr
26-02-2018	BHARTI TRANSFER TXN		15,000.00		19,80,951.77Cr
26-02-2018	RTGSCENTER FOR PUBLIC HEALT			9,74,387.00	29,55,338.77Cr
26-02-2018	RTGSCENTER FOR PUBLIC HEALT			17,79,732.00	47,26,070.77Cr
27-02-2018	By Inst.020661/CAHARA/			500.00	47,26,570.77Cr
27-02-2018	ATUL KUMAR TRANSFER TXN	540926	12,000.00		47,14,570.77Cr
27-02-2018	DHARAM RAJ .TRANSFER TXN	540927	10,000.00		47,04,570.77Cr
27-02-2018	VED PAL	540912	45,923.00		46,58,647.77Cr
27-02-2018	TANVI CHAUDHARY	540903	84,382.00		45,74,265.77Cr
27-02-2018	SURENDER KUMAR	540925	35,000.00		45,39,265.77Cr
27-02-2018	e	540636	2,000.00		45,37,265.77Cr

Page Total Credit : 29,23,121.00
Page Total Debit : 9,08,584.00

Registrer
Swami Vivekanand
Subharti University
MEERUT

IDBI BANK LTD.
IDBI COMPLEX
CAL BUNGLOW OFF C G ROAD
AHMEDABAD - 380006

भारत STAMP DUTY ગુજરાત
SPECIAL ADHESIVE
Rs. 0000100 20.3.2017

CLINICAL STUDY AGREEMENT

CLINICAL STUDY AGREEMENT BETWEEN THE SPONSOR, CADILA HEALTHCARE LIMITED, Zydus Towers, Satellite Cross Roads, Ahmedabad-380015, India and

Dr. Saurabh Singhal, Subharti Medical College, Subhartipuram NH 58, Delhi-Haridwar Bypass Road, Meerut - 250005

And

Dr.A K Asthana, Principal & Dean, Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005

Project : ZYAN1.16.001
Protocol No.: ZYAN1.16.001.01.PROT
This Clinical Study Agreement ("Agreement") between

1. CADILA HEALTHCARE LIMITED, ZYDUS TOWERS, SATELLITE CROSS ROADS, AHMEDABAD-380015, INDIA (HEREAFTER REFERED AS "THE SPONSOR") AND
2. Dr. Saurabh Singhal, Subharti Medical College, Subhartipuram, NH 58, Delhi - Haridwar Bypass Road, Meerut-250005, and
3. Subharti Medical College, Subhartipuram, NH 58, Delhi - Haridwar Bypass Road, Meerut-250005

When signed by all parties, is effective from last date of Signature

THE SPONSOR wishes to sponsor a clinical study entitled "A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase II Multi-Centric Trial to Assess Safety, Tolerability and Efficacy of PHD-2 Inhibitor, ZYAN1 in the Treatment of Anemia in Pre-Dialysis Chronic Kidney Disease Patients.".
Centre Subharti Medical College, Meerut to be conducted at Institution. This agreement also covers any companion protocol(s), later developed and approved by both/three parties, that are conducted concurrently with the protocol identified above (collectively, "Protocol") and that involve some or all of the same subjects (collectively, "Study"). The sponsor hereby declares that all the necessary permissions and licenses required under the provision of relevant acts and rules namely Drug & Cosmetics Act and Drug & Cosmetic Rules 1945 and their subsequent amendments (including Schedule Y) are obtained by them for the use of the same on the study subjects.

THE PARTIES AGREE AS FOLLOWS

1. The sponsor would like to test the drug namely ZYAN1 which will be used in patients suffering from Treatment of anemia in chronic kidney disease patients. The sponsor hereby declares that all the necessary permissions and licenses required under the provision of relevant acts and rules namely Drug & Cosmetics Act and Drug & Cosmetic Rules 1945 and their subsequent amendments (including Schedule Y) are obtained by them for the use of the same on the study subjects.
2. The sponsor have approached the investigator as they desire to perform the study in regards to the said drug in accordance with the applicable guidelines on Good Clinical Practice, ethics and local regulations.
3. The Principal Investigator hereby confirms that he has read and understood the Clinical Trail protocol entitled "A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase II Multi-Centric Trial to Assess Safety, Tolerability and Efficacy of PHD-2 Inhibitor, ZYAN1 in the Treatment of Anemia in Pre-Dialysis Chronic Kidney Disease Patients". All amendments and appendices have also been read and understood. The investigator agrees to the protocol "A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase II Multi-Centric Trial to Assess Safety, Tolerability and Efficacy of PHD-2 Inhibitor, ZYAN1 in the Treatment of Anemia in Pre-Dialysis Chronic Kidney Disease Patients.".
4. and will perform the study in accordance with the applicable guidelines on Good Clinical Practice, ethics and local regulations.

Investigators and Research Staff.

4.1. Principal Investigator. The Study will be conducted Dr. Saurabh Singhal (HEREAFTER REFERED AS "PRINCIPAL INVESTIGATOR") at Subharti Medical College, Subhartipuram NH 58, Delhi-Haridwar Bypass Road, Meerut-250005The term "Investigator" as used in this Agreement refers, as applicable, to the Principal Investigator, subinvestigators, research staff or the Institution or all or any of them.

4.2. Subinvestigators and Research Staff. Investigator will ensure that only individuals, who are appropriately trained and qualified, assist in the conduct of the Study as subinvestigators or research staff.

4.3. Obligations. Institution will ensure that all personnel, who assist in the conduct of the Study, are informed of and agree to abide by all terms of this Agreement applicable to the activities they perform. Institution is responsible to THE SPONSOR for compliance by all Study personnel, including THE PRINCIPAL INVESTIGATOR, with the terms of this Agreement.

4.4. No Substitution. Institution shall not reassign the conduct of the Study to a different Principal Investigator without prior written authorization from THE SPONSOR.

4.5. Delegation of Duties by Principal Investigator. Principal Investigator may delegate duties and responsibilities to subinvestigators or research staff only to the extent permitted by the relevant laws and regulations governing the conduct of clinical investigations in India.

4.6. Compliance with Institutional Policies. Principal Investigator will comply with the policies and procedures of the organization(s) with which Principal Investigator is affiliated, including any applicable financial policies. Principal Investigator will notify THE SPONSOR promptly of any conflict between the terms of this Agreement and any such policy or procedure, and the parties will attempt to reach an appropriate accommodation.

5. Funding. THE SPONSOR will provide mutually agreed upon funding in support of this Study as set out in Attachment A and subject to the terms specified in that Attachment.

6. Protocol. Investigator will conduct the Study in accordance with the Protocol, ICH GCP guidelines and applicable rules and regulations in India.

6.1. Amendments. The Protocol may be modified only by a written Amendment, signed by both THE SPONSOR and THE PRINCIPAL INVESTIGATOR.

6.2. Emergency Amendments. If it is necessary to change the Protocol on an emergency basis for the safety of the subjects, Investigator will notify THE SPONSOR and the responsible Independent Ethics Committee or Institutional Review Board (as applicable) as soon as practicable but, in any event, not later than five working days after the change is implemented. Any emergency change to the Protocol must be followed by a written Amendment.

6.3. No Additional Research. No additional research may be conducted on Study subjects during the conduct of the Study unless it is approved and documented as a sub-study protocol or an Amendment to the original Protocol. Such prohibited research activities include, but are not limited to, analyses of biological samples from Study subjects for any non-therapeutic purpose.

7. Subject Enrollment. Investigator has agreed to enroll in Study a minimum of 10 subjects by 3 month unless THE SPONSOR extends this enrollment period by written notification. A qualified subject is one who meets all Protocol criteria such as inclusion & exclusion criteria and agrees to participate in the study through informed consent in writing.

7.1. Excess Enrollment. If Investigator enrolls the maximum number of qualified subjects before the deadline, THE SPONSOR may or may not invite Investigator to enroll additional subjects. However, The Institution and/or THE PRINCIPAL INVESTIGATOR shall not enroll more than 15 subjects without prior approval by THE SPONSOR.

7.2. Failure to Enroll. If Investigator fails to enroll subjects at a rate adequate to meet the enrollment requirement, THE SPONSOR shall be free to terminate the Study early (see Section 25, Termination).

8. Study Conduct. Investigator will conduct Study in accordance with the Protocol, THE SPONSOR's written instructions, International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines and all applicable governmental laws, rules, and regulations.

8.1. No Charge for Investigational Drug or Reimbursed Services. Investigator will not charge a Study subject or third-party payer for Investigational Drug (see Section 13, Investigational Drug) or for any services reimbursed by THE SPONSOR under this Agreement.

9. Independent Ethics Committee/Institutional Review Board. Before the Study is initiated, Investigator will ensure that both the Study and the informed consent form are approved by an Independent Ethics Committee or Institutional Review Board (as applicable)(both referred to as a "IRB") that complies with all applicable laws and regulations. Investigator will further ensure that the Study is subject to continuing oversight by the IRB throughout its conduct.

9.1. Study Disapproval. If, through no fault of Investigator, the Study is disapproved by the IRB, this Agreement will immediately terminate with no penalty to the Investigator, as provided in Section 25.1a, Disapproval by IRB, below.

10. Data Protection. Data collected in Study may include personal data and sensitive personal data which is subject to specific legislation relating to the processing, storage, transfer and use of such data Investigator will comply with all relevant laws relating to the protection and use of personal data and data privacy in its conduct and reporting of the Study. The Investigator shall take all technical and organizational measures to prevent unauthorized or unlawful processing or accidental loss or destruction of, or damage to, or disclosure of such data. THE SPONSOR will take appropriate measures to protect the confidentiality and security of all personal data that it receives from Investigator in connection with the Study. Personal data relating to the Investigator shall be processed and used for the purposes of administration of this agreement and in connection with the Study and will be held on one or more databases for the purposes of determining the Investigator's involvement in future research and in order to comply with any regulatory requirements. Such data may be disclosed or transferred to other members of Cadila Healthcare Limited group of companies, to representatives and contractors working on behalf of THE SPONSOR group and to regulatory authorities across the world. The Investigator shall ensure that all necessary consents are in place to comply with the provisions of this clause.

11. Informed Consent and Authorization to Use and Disclose Health Information

11.1. Informed Consent. Investigator will provide THE SPONSOR an opportunity to review and approve the content of the informed consent form (including any revisions made during the course of the Study) before it is used. Investigator will obtain a written informed consent from each Study subject and will maintain a signed original of that consent in the subject's record. Investigator will allow THE SPONSOR to inspect signed informed consent forms or photocopies there of during monitoring visits or audits (see Monitoring and Audits, Section 17).

12. Adverse Events. Investigator will report adverse events experienced by Study subjects in accordance with instructions in the Protocol and applicable regulations. This includes, where required, prompt reporting by telephone or facsimile. THE SPONSOR shall, so far as is lawful, have full responsibility for the reporting of all adverse events to local and international regulatory and/or health authorities.

13. Investigational Drug. THE SPONSOR will provide Investigator with sufficient quantities of the investigational drug(s) needed to conduct the study.

13.1. Custody and Dispensing THE PRINCIPAL INVESTIGATOR will maintain appropriate control of supplies of Investigational Drug and will not provide it to anyone else except subinvestigators or research staff. THE PRINCIPAL INVESTIGATOR shall maintain the records of inventory of the Investigational drug.

13.2. Use. Investigator will use Investigational Drug only as specified in the Protocol. Any other use of Investigational Drug constitutes a material breach of this Agreement.

13.3. Ownership of Investigational drug. Investigational drug and remains the property of THE SPONSOR except for, and limited to, the use specified in the Protocol, THE SPONSOR grants Investigator no express or implied intellectual property rights in Investigational drug or in any methods of making or using Investigational drug.

14. Equipment. The SPONSOR may provide certain equipment for use by the Investigator during the conduct of the study ("Equipment").

14.1. Ownership and Use. Equipment is and remains the property of THE SPONSOR and INVESTIGATOR may use Equipment only for purposes of the study.

14.2. Investigator Responsibilities. Investigator will comply with any operating and maintenance instructions provided by THE SPONSOR or the manufacturer and will store Equipment under conditions that are appropriate to the nature f the Equipment and that minimize the risk of loss or damage.

14.3. Liability. THE SPONSOR has no liability for damages of any sort, including personal injury or property damage, resulting from the use of Equipment except to the extent that such damages were caused by negligence or willful misconduct of THE SPONSOR.

15. Confidential Information. During the course of the Study, Investigator may receive or generate information that is confidential to THE SPONSOR

15.1. Definition. Except as specified in Section 15.2, Exclusions, below, "Confidential Information" includes

a. the Protocol,
b. the Investigator Brochure,
c. Study Data (as defined in Section 16, Study Data, Biological Samples, and Study Records, below), subject to Investigator's right to publish the results of the Study (as described in Section 19, Publications, below),
d. Biological Sample Analysis Data (as defined in Section 15, Study Data, Biological Samples, and Study Records, below).
e. Any other information related to the study, the investigator drug or Sponsor technology, research or business plans that sponsor provides to the investigator in writing or other tangible form and marks as CONFIDENTIAL or initially discloses orally and then summarize and confirms in writing as CONFIDENTIAL within 90 days after the date of oral disclosure.

15.2. Exclusions. Confidential Information does not include information that (i) is known or open to the public or otherwise in the public domain at the time of disclosure or (ii) becomes part of the public domain during the term of this confidentiality obligation by any means other than breach of this Agreement by Investigator (iii) is already known to Investigator at the time of disclosure and is free of any obligations of confidentiality, or (iv)is obtained by Investigator, free of any obligations of confidentiality, from a third party that has a lawful right to disclose it.

15.3. Obligations of Confidentiality. Unless THE SPONSOR provides prior written consent, Investigator may not use Confidential Information for any purpose other than that authorized in this Agreement, nor may Investigator and or Institute disclose Confidential Information to any third party except as authorized in this Agreement or as required by law.

a. Required disclosure of Confidential Information to the IRB or to regulatory representatives is specifically authorized.
b. Publication of the results of the Study based on Study Data collected or generated by Investigator is specifically authorized, of this Agreement.

15.4. Disclosure Required by Law. If disclosure of Confidential Information to any party other than the Independent Ethics Committee, relevant regulatory authority is required by law, that disclosure does not constitute a breach of this Agreement so long as Investigator

a. notifies THE SPONSOR in writing in 15 working days advance of the disclosure so as to allow THE SPONSOR to take legal action to protect its Confidential Information,
b. discloses only that Confidential Information required to comply with the legal requirement, and
c. continues to maintain the confidentiality of this Confidential Information with respect to all other third parties.

15.5. Individually Identifiable Health Information. If, in connection with this Study or performance of this Agreement, THE SPONSOR comes into contact with individuality identifiable health information relating to subjects who are not Study subjects, THE SPONSOR agrees to maintain the confidentiality of such information and not to use it for any purpose.

15.6. Survival of Obligations. These obligations of confidentiality survive termination of this Agreement and continue for a period of five years after completion of the study or termination, which ever is earlier.

15.7. Return of Confidential Information. If requested by THE SPONSOR in writing, Investigator will return all Confidential Information except that required to be retained at the Study site by law. However, Investigator may retain a single archival copy of the Confidential Information for the sole purpose of determining the scope of obligations incurred under this Agreement.

16. Study Data, Biological Samples and Study Records.

16.1. Study Data. During the course of the Study, Investigator will collect and submit certain data to THE SPONSOR or its agent, as specified in the Protocol. This may include case report forms or their equivalent ("Case Report Forms"), or other types of medical images, ECG, or other types of tracings or printouts, data summaries, or any combination of these (collectively, "Study Data"). Investigator will ensure accurate and timely collection, recording, and submission of Study Data. Investigator will deliver Study Data to THE SPONSOR or its agent within the time periods specified below.

a. Ownership of Study Data. Subject to Investigator's right to publish the results of the Study (see Section 19, Publications), THE SPONSOR is the exclusive owner of all Study Data.

b. Non-exclusive License. THE SPONSOR grants Institution a royalty free non-exclusive license, with no right to sublicense, to use Study Data (not related with the investigator drug) for internal research or educational purposes.

c. Data Management and statistical Analysis: THE SPONSOR or its representative shall carry out the data management and statistical analysis. THE SPONSOR may consult and / or provide THE PRINCIPAL INVESTIGATOR for interpretation during report writing.

d. THE SPONSOR is the exclusive owner of study data.

16.2. Biological Samples. If so specified in the Protocol, Investigator may collect and provide to THE SPONSOR or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Study subjects for testing that is directly related to subject care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing ("Biological Samples").

a. Use. Investigator will not use Biological Samples collected under the Protocol in any manner or for any purpose other than that described in the Protocol.

b. Analysis samples. THE SPONSOR or its designees will test Biological Samples as described in the Protocol. Unless otherwise specified in the Protocol, THE SPONSOR will provide the results of these tests ("Biological Sample Analysis Data") to the Investigator or Study subject.

c. Ownership. THE SPONSOR is the exclusive owner of all Biological Samples and Biological Sample Analysis Data.

16.3. Study Records. Investigator will ensure that subject's Study records, which include the Investigator's copies of all Study Data as well as relevant source documents (collectively, "Study Records"), are kept up to date and maintained in accordance with applicable regulations and institutional guidelines.

a. Retention. Investigator will retain Study Records, under storage conditions conducive to their stability and protection, for a period of 15 years after termination of the Study unless THE SPONSOR authorizes, in writing, earlier destruction. Investigator agrees to notify THE SPONSOR before destroying any Study Records after the required retention period. Investigator further agrees to permit THE SPONSOR to ensure that the records are retained for a longer period if necessary, at THE SPONSOR expense, under an arrangement that protects the confidentiality of the records (e.g., secure off-site storage).

17. Monitoring, Inspections and Audits.

17.1. Monitoring. THE SPONSOR shall be entitled at its absolute discretion (and in such form as THE SPONSOR sees fit) to monitor and audit the conduct of the Study. Upon reasonable notice, Institution will permit THE SPONSOR representatives access to the premises, facilities, procedures and records relating to the Study, investigators, and research staff as required to accomplish this. The Institution agrees to co-operate and provide all reasonable assistance with any monitoring and/or auditing activity. No such monitoring and/or auditing by THE SPONSOR will relieve the Investigator of any of its obligations hereunder.

17.2. Inspections and Audits. The Study is subject to inspection by regulatory agencies worldwide. Regulatory inspections may occur after completion of the Study and may include auditing of Study Records. Auditing involves comparison of Case Report Forms or Data Records with the source documentation on which they are based. THE SPONSOR may also choose to audit Study Records as part of its monitoring of Study conduct.

a. Notification. Investigator will notify THE SPONSOR as soon as reasonably possible if the site is inspected or scheduled to be inspected by a regulatory agency.

b. Cooperation. Investigator will cooperate with regulatory agency or THE SPONSOR representatives in the conduct of inspections and audits and will ensure that Study Records are maintained in a way that facilitates such activities.

c. Resolution of Discrepancies. Investigator will promptly resolve any discrepancies that are identified between the Study Case Report Forms and the subject's medical records.

d. Inspection Findings and Responses. Investigator will promptly forward to THE SPONSOR copies of any inspection findings that Investigator receives from a regulatory agency. Whenever feasible, Investigator will also provide THE SPONSOR with an opportunity to prospectively review and comment on any Investigator responses to regulatory agency inspections.

e. Data Clarification Form: THE SPONSOR may raise data clarification forms (queries) during or after the monitoring and/or auditing and/or statistical review of the study, which THE INSTIUTION OR THE PRINCIPAL INVESTIGATOR shall clarify within 7 working days.

f. Study Conduct Evaluations. THE SPONSOR or its external service providers may document and evaluate the performance of Investigator in the conduct of the Study. THE SPONSOR will use these evaluations solely for internal purposes.

18. Inventions.

18.1. Notification. If the conduct of Study results in any invention or discovery whether patentable or not ("Invention"), Investigator will promptly inform THE SPONSOR.

18.2. Assignment. Investigator will assign all interest in any such Invention to THE SPONSOR, free of any obligation or consideration beyond that provided for in this Agreement.

18.3. Assistance. Investigator will provide reasonable assistance to THE SPONSOR in filing and prosecuting any patent applications relating to Invention, at THE SPONSOR's expense.

19. Publications.

19.1. Prepublication Review. THE SPONSOR has no objection to publication by Investigator of any information collected or generated by Investigator, whether or not the results are favorable to the Investigational Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Investigator will provide THE SPONSOR an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed. The timing of such publication shall be mutually agreed upon.

a. Submission to THE SPONSOR: Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to THE SPONSOR at least 90 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 360 days.

b. Redaction of Confidential Information. Investigator will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.

20. Indemnification. THE SPONSOR will provide an indemnity to the Institution in respect of the Study (Annexure B).

21. Debarment and Exclusion. Institution and Principal Investigator each certify that it/s/he is not debarred and that it/s/he is not and will not use in any capacity the services of any person debarred under such law with respect to services to be performed under this Agreement. During the term of this Agreement and for three years after its termination, Institution and Principal Investigator will notify THE SPONSOR promptly if either of these certifications needs to be amended in light of new information.

22. Use of Name. Neither party will use the name of the other party or any of its employees for promotional or advertising purposes without written permission from the other party. However, THE SPONSOR reserves the right to identify THE PRINCIPAL INVESTIGATOR and Institution in association with a listing of the Protocol in publicly available listings of ongoing clinical trials, or other subject recruitment services or mechanisms.

23. Assignment and Delegation.

23.1 Institution may not assign its rights or delegate or subcontract any duties under this Agreement without written permission from THE SPONSOR any attempt to so assign, delegate, or subcontract is invalid. If THE SPONSOR authorizes delegation or subcontracting, Institution remains responsible to THE SPONSOR for the performance of all delegated duties.

23.2 THE SPONSOR may not assign its rights or delegate its duties under this Agreement without written permission from Institution. Any attempt to so assign or delegate is invalid. However, THE SPONSOR may freely subcontract Study-related duties to an external provider upon advance notice to Institution, and also may freely assign its rights or delegate its duties to any THE SPONSOR affiliate. If THE SPONSOR delegates or subcontracts any duties, THE SPONSOR remains responsible to Institution for the performance of those duties.

23.3 Affiliates. As used in this Agreement, the term "affiliate" means any entity that directly or indirectly controls, is controlled by, or is under common control with THE SPONSOR

23.4 Successors and Assigns. This Agreement will bind and inure to the benefit of the successors arid permitted assigns of each party.

24. Conflict with Attachments. If there is any conflict between this Agreement and any Attachments to it, or between this Agreement and the Protocol, the terms of this Agreement control.

25. Termination.

25.1. Termination Conditions. This Agreement terminates upon the earlier of any of, the following events:

a. Disapproval by IRB. If, through no fault of Investigator, the Study is never initiated because of IRB disapproval, this Agreement will terminate immediately.

b. Study Completion. For purposes of this Agreement, the Study is considered complete after conclusion of all Protocol-required activities for all enrolled subjects; receipt by THE SPONSOR of all Protocol-required data and Biological Samples; and receipt of all payments due to either party.

c. Termination Upon Notice: THE SPONSOR reserves the right to terminate the Study for any reason upon 30 days written notice to Investigator.

d. Immediate Termination by THE SPONSOR: THE SPONSOR further reserves the right to terminate the Study immediately upon written notification to Investigator for causes that include, but are not limited to, failure to enroll subjects at a rate sufficient to achieve Study performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in THE SPONSOR 's opinion pose risks to the health or ell being of Study subjects; or regulatory agency actions relating to the Study or the Investigational Drug.

e. Termination Upon Notice by Investigator: THE PRINCIPAL INVESTIGATOR may terminate the study, if THE SPONSOR does not comply with the agreement related to finance, supply of medication for the study and supply of related material. Written notice of any such termination by principal investigator including the reasons therefore shall be provided by registered mail to THE SPONSOR fifteen days prior to termination and THE SPONSOR shall have fifteen days to cure its default.

f. Immediate Termination by Investigator. Investigator reserves the right to terminate the Study immediately upon notification to THE SPONSOR if requested to do so by the responsible IRB or if such termination is required to protect the health of Study subjects.

g. Payment upon Termination. If the Study is terminated early in accordance with Section 25.1. Termination Conditions, above, THE SPONSOR will provide a termination payment equal to the amount owed for work already performed, in accordance with Attachment A, less' payments already made. If the Study was never initiated because of disapproval by the IRB (see Section 25.1a, Disapproval by IRB, above), THE SPONSOR will reimburse Investigator for IRB fees and for any other expenses that were prospectively approved, in writing, by THE SPONSOR

h. Return of Materials. Unless THE SPONSOR instructs otherwise in writing, Investigator will promptly return all materials supplied by THE SPONSOR for Study conduct, including unused Investigational Drug, unused Case Report Forms, other study related material and any THE SPONSOR - supplied Equipment.

i. Treatment Code (Blinded Studies Only). Upon request, THE SPONSOR will provide Investigator with a treatment assignment list that identifies, by subject number, the treatment that each Study subject received. Unless otherwise specified in the Protocol, THE SPONSOR will provide such treatment assignment information only after the Study is completed (or has been terminated and all data submitted) at all participating sites.

j. Survival of Obligations. Obligations relating to Funding, Confidential Information, Study Records, Inventions, Publications, Indemnification, and Debarment and Exclusion survive termination of this Agreement, as do any other provision in this Agreement or its Attachments that by its nature and intent remains valid after the term of the Agreement.

26. Modification. Any alteration, modification or amendment to this Agreement must be in writing and signed by each of the parties.

27. Entire Agreement. This Agreement and any Exhibits and Attachments represent the entire understanding between the parties relating to the conduct of this Study. This Agreement supersedes all previous agreements between the parties (oral and written) relating to this Study, except for any obligations that, by their terms, survive termination.

28. This agreement shall be interpreted and enforced under the laws of India. All disputes arising hereunder shall be submitted to the exclusive jurisdiction of courts at defendant's place.

Executed by the parties
Cadila Healthcare Limited

Dr.Dinesh V.Parmar
Vice President and Head Clinical R&D
Date: 26/05/17

Mr.Nitin Parekh
C.F.O
Date: 26/05/17

I have read and understand this Agreement and accept the terms as they relate to my activities as Principal Investigator. I further agree to ensure that all subinvestigators and research staff are informed of their obligations under this Agreement.

Principal Investigator

Dr. Saurabh Singhal
Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005
Date: 1.4.2017

The Institution

Dr. A. K. Asthana
Principal & Dean
Subharti Medical College, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut-250005
Date: 1.4.2017

HDFC BANK

Cash Management Services - Payments

MAIL TO

Subharati K K B Charitable Trust

Delhi Haridwar By pass roadSubharti Medical College,Subharti Puram,NH 58Meerut

BY ORDER OF

CADILA HEALTHCARE LIMITED
ZYDUS TOWER,SATELLITE CROSS RD
AHMEDABAD-380 015

Cheque no:	095253	Cheque amount:	******30,000.00
Value date:	11/04/2017	Bene Code:	224198
Bank Ref No:	FT704117722448	Customer Ref. No.	3401002232

Srno	Inv.No	Doc. No	Doc. Date	Gross Amt	TDS	Net Amount
001	RABIMABS	3301000207	03/04/17	33334.00	3334	30000.00
				33334.00	3334	30000.00

Dr. Abhishek
Rabies vaccine

Registrer
Swami Vivekanand
Subharti University
MEERUT

HDFC BANK

A/c Payee Not Negotiable

RAL TOWERS,
RELIANCE GEN.INSU.
JI MITHAKALI SIX ROAD,
RANGPURA, AHMEDABAD-380 009

IFSC HDFC0000008

CMS DISBURSEMENT CHEQUE
VALID FOR THREE MONTHS FROM THE DATE OF ISSUE

1	1	0	4	2	0	1	7

PAY Subharati K K B Charitable Trust

OR ORDER/आदेश अनुसा

RUPEES/रुपये THIRTY THOUSAND ONLY **

अदा करें | ₹ | ******30,000.00

A/c No. खाता सं. 00060310000747

PAYABLE AT PAR AT ALL CLEARING BRANCHES OF HDFC BANK LTD.

VOID

FOR CADILA HEALTHCARE LIMITED

Authorised Signatory

Please sign above

⑈095253⑈ 380240002⑆ 90▮066⑈ 30

HDFC BANK

Cash Management Services - Payments

MAIL TO

Subharati K K B Charitable Trust

Delhi Haridwar By pass roadSubharti Medical College,Subharti Puram,NH 58Meerut

BY ORDER OF

CADILA HEALTHCARE LIMITED
ZYDUS TOWER,SATELLITE CROSS RD
AHMEDABAD-380 015

Cheque no:	172376	Cheque amount:	******41,219.00
Value date:	13/02/2018	Bene Code:	224198
Bank Ref No:	FT802130068445	Customer Ref. No.	3401096400

Srno	Inv.No	Doc. No	Doc. Date	Gross Amt	TDS	Net Amount
001	REBIMABS	3301062093	06/02/18	45128.00	3909	41219.00
				45128.00	3909	41219.00

Registrer
Swami Vivekanand
Subharti University
MEERUT

13/2/18

HDFC BANK

ASTRAL TOWERS,
OPP RELIANCE GEN BUS,
NEAR MITHAKALI SIX ROAD,
NAVRANGPURA, AHMEDABAD-380 009

A/c Payee Not Negotiable

IFSC HDFC0000008

CMS DISBURSEMENT CHEQUE
VALID FOR THREE MONTHS FROM THE DATE OF ISSUE

1 3 0 2 2 0 1 8

PAY Subharati K K B Charitable Trust

OR ORDER/आदेश अनुसार

RUPEES/रुपये FORTY-ONE THOUSAND TWO HUNDRED NINETEEN ONLY **

अदा करें ₹ ******41,219.00

A/c No. खाता सं. 00060310000747

PAYABLE AT PAR AT ALL CLEARING BRANCHES OF HDFC BANK LTD

VOID

FOR CADILA HEALTHCARE LIMITED

Dr. Abhishek Gupta Rabies vaccine

Authorised Signatory

Please sign above

BANG DATA FORMS CTS 2010 1/16

"172376" 380240002: 901066" 30

To

S.No. 2018-19/173 dated 25.07.2018

The Registrar
SWAMI VIVEKANAND SUBHARTI UNIVERSITY
NH-58, Delhi Haridwar Bypass Road
Subhartipuram, Meerut
(U.P.)

Sub.: Release of Grant in Aid for Undertaking Research Activities related to Himalayan Folk Art and Culture as recommended by the Management Committee of Younker Historical Research Foundation.

Dear Sir,

Please find enclosed a cheque no. 026260 of Rs. 75,000/- (Rupees Seventy Five Thousand Only) dated 25.07.2018 drawn on Union Bank of India being the grant-in-aid sanction vide no 2018-19/173 details as under :

Sl.	Topic of Research	Name of Investigator	Amount Sanction
1.	Research and Documentation of the Garhwali Art and Sculpture	Dr. Pooja Gupta Professor and Head, Department of Painting Swami Vivekanand Subharti University	20,000.00
2.	Documentation of Garhwal Cuisine	Mr. Sunil Kumar Panwar Assistant Professor Bhikaji Cama Subharti College of Hotel Management, Swami Vivekanand Subharti University	15,000.00
3.	Documentation of the Festivals of Gangotri	Dr. Neeraj Karan Singh Principal Ganesh Shankar Vidyarthi Subharti College of Jofirnalism and Mass	20,000.00

		Communication, Swami Vivekanand Subharti University	
4.	Documentation of Folklore and Proverbs of Uttrakhand	Dr. Tusthi Sharma, Associate Professor, Department of Languages, Swami Vivekanand Subharti University	20,000.00

Please acknowledge the receipt of the same.

Yours truly,

(Dr. Harish Kumar)
Executive Secretary

CC to :

1. Dr. Pooja Gupta, Head Painting department, NBSCFF, Swami Vivekanand, Subharti University, Meerut, U.P.
2. Mr. Sunil Kumar Panwar, Assistant Professor, Bhikaji Cama Subharti College of Hotel Management, Swami Vivekanand, Subharti University, Meerut, U.P.
3. Dr. Neeraj Karan Singh, Principal, Ganesh Shankar Vidyarthi Subharti College of Mass Communicaation and Journalism, Swami Vivekanand, Subharti University, Meerut, U.P.
4. Dr. Tushti Sharma, Associate Professor, Department of Languages, Swami Vivekanand, Subharti University, Meerut, U.P.

Yours truly,

(Dr. Harish Kumar)
Executive Secretary

Registrer
Swami Vivekanand
Subharti University
MEERUT

Union Bank of India

हापुड़ शाखा, गाजियाबाद - 245 101
Hapur Branch, Ghaziabad - 245 101
IFS CODE : UBIN0530620

VALID FOR 3 MONTHS FROM THE DATE OF ISSUE

दिनांक DATE 2 5 0 7 2 0 1 8
D D M M Y Y Y Y

10X28

PAY SVSU EDU PROMOTION A/C H OBC 52282113000365 या धारक को OR BEARER

रुपये RUPEES Seventy five thousand only

₹ 75,000/-

अदा करें

खाता सं. A/c No.	306202010907905	चेक क्र. Cheque No.	33026060

Heero Hito

YOUNKER HISTORICAL RESEARCH FOUNDATION

Heero Hito

PLEASE SIGN ABOVE THIS LINE

भारत की सभी शाखाओं में सममूल्य पर देय
PAYABLE AT PAR AT ALL OUR BRANCHES IN INDIA

⑈026060⑈ 000026000⑆ 306233⑈ 31

Registrar
Swami Vivekanand
Subharti University
MEERUT

शाक्यामुनि बुद्धा राष्ट्रीय प्रौद्योगिकी प्रबंधन एवं ग्रामीण विकास संस्थान

Sakyamuni Buddha National Institute For Rural Development, Management and Technology

Krishna Vihar, Post Jakhan, Distt-Dehradun-248001 Uttrakhand India
Email- smbnational2004@gmail.com Telephone +91-9084666444

Ref.SMB/03-04/2017-18/02 Date:02-01-2018

To,

DR. MAMTA TYAGI

Department Of Obstetrics & Gynaecology,

Subharti Medical College

Dear DR. MAMTA TYAGI,

After thoroughly evaluating your project **"A study to evaluate and compare the expulsion,removal and continuation of post placentalinsertion of cu 375, cut 380a and lng-ius in indian women at a tertiary care centre"**, we are delighted to advise you that we are willing to fund the project up to **INR 4500/-** in consumables. Please submit the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Yanki

President

President/Secretary
SMB National Institute of RuDMaTech
Dehradun, Uttrakhand

शाक्यामुनि बुद्धा राष्ट्रीय प्रौद्योगिकी प्रबंधन एवं ग्रामीण विकास संस्थान

Sakyamuni Buddha National Institute For Rural Development, Management and Technology

Krishna Vihar, Post Jakhan, Distt-Dehradun-248001 Uttrakhand India
Email- smbnational2004@gmail.com Telephone +91-9084666444

Ref.SMB/03-04/2017-18/04 Date:02-01-2018

To,

DR. YASHPAL MONGA

Department Of Surgery,

Subharti Medical College

Dear DR. YASHPAL MONGA,

After thoroughly evaluating your project "**Comparative study of dartos muscle flap and tunica vaginalis flap in tubularised incised plate urethroplasty in hypospadias**", we are delighted to advise you that we are willing to fund the project up to **INR 4900**/- in consumables. Please submit the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Yanki

President

President/Secretary
SMB National Institute of RuDMaTech
Dehradun, Uttrakhand

शाक्यामुनि बुद्धा राष्ट्रीय प्रौद्योगिकी प्रबंधन एवं ग्रामीण विकास संस्थान

Sakyamuni Buddha National Institute For Rural Development, Management and Technology

Krishna Vihar, Post Jakhan, Distt-Dehradun-248001 Uttrakhand India
Email- smbnational2004@gmail.com Telephone +91-9084666444

Ref.SMB/03-04/2017-18/05 Date:09-01-2018

To,

Dr. Avinash Rastogi

Department of Orthopaedics,

Subharti Medical College

Dear Dr. Avinash Rastogi,

After thoroughly evaluating your project "**Evaluaton of functional outcome of flexible intramedullary nailing in fracture shaft of clavicle**", we are delighted to advise you that we are willing to fund the project up to **INR 2600/-** in consumables. Please submit the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Yanki

President

President/Secretary
SMB National Institute of RuDMaTech
Dehradun, Uttrakhand

शाक्यामुनि बुद्धा राष्ट्रीय प्रौद्योगिकी प्रबंधन एवं ग्रामीण विकास संस्थान
Sakyamuni Buddha National Institute For Rural Development, Management and Technology

Krishna Vihar, Post Jakhan, Distt-Dehradun-248001 Uttrakhand India
Email- smbnational2004@gmail.com Telephone +91-9084666444

Ref.SMB/03-04/2017-18/06 Date:09-01-2018

To,

Dr. FARHAT ABRAR

Department Of Ophthalmology,

Subharti Medical College

Dear Dr. FARHAT ABRAR,

After thoroughly evaluating your project **"Serum cortisol and serum testosterone levels in idiopathic central serous chorioretinopathy"**, we are delighted to advise you that we are willing to fund the project up to **INR 4900**/- in consumables. Please submit the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Yanki

President

President/Secretary
SMB National Institute of RuDMaTech
Dehradun, Uttrakhand

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/29 Date: 13-02-2018

To,

DR. SANJAY KUMAR

Department Of Otorhinolaryngology,

Subharti Medical College

Dear DR. SANJAY KUMAR,

After carefully going through the project "**Correlation of clinical findings with ossicular pathology in chronic otitis media**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 3000/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2018-19/55 Date: 03-01-2019

To,

Dr. MUKTA MITAL

Department of Radio diagnosis & Imaging,

Subharti Medical College

Dear Dr. Mital,

After carefully going through the project "**Clinical utility of breast ultrasound as an adjunct tomammography in screening and diagnostic imaging**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 1800/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/24 Date: 07-02-2018

To,

DR. ASTHA AGARWAL

Department of Pediatrics,

Subharti Medical College

Dear Dr. AGARWAL,

After carefully going through the project "**Spectrum of behavioral problems in adolescents attending tertiary care hospital**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of INR 2300/- in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/25 Date: 08-02-2018

To,

Dr. Saurabh Singhal

Department of Medicine,

Subharti Medical College

Dear Dr. Singhal,

After carefully going through the project "**Study prevalence, severity and risk factors of symptomatic gastro-esophageal reflux disease among workers of large hospital in western uttar pradesh**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 2500/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation
Secretary
Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/31 Date: 15-02-2018

To,

DR. ANJALI KHARE

Department Of Pathology,

Subharti Medical College

Dear Dr.Khare,

After carefully going through the project "**Role of platelet volume indices in diagnostic approach of thrombocytopenia**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 3000/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/30 Date: 14-02-2018

To,

Dr. ARVIND KRISHNA

Department Of Dermatology, Venereology And Leprosy,

Subharti Medical College

Dear Dr. Krishna,

After carefully going through the project "**An observational study describing dermoscopic features of common macular facial hyperpigmented skin lesions**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 1400/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/28 Date: 12-02-2018

To,

DR.(Prof.) SHASHANK MISHRA

Department Of General Surgery,

Subharti Medical College

Dear Dr. Mishra,

After carefully going through the project "**Evaluation and management of gall bladder stone disease using "ichbs (intraoperative clinical hepato-biliary score) system**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 1300/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/27 Date: 10-02-2018

To,

Dr. SMRITI GUPTA

Department Of Obstetrics & Gynaecology,

Subharti Medical College

Dear Dr. Gupta,

After carefully going through the project "**Anemia and its effect on thyroid profile in pregnant women in tertiary care centre**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 1600/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

YBSRF

Reg.No. 1038/78-79 Reg.Date 30.06.1978

YOUNKER BUDDHIST SOCIETY AND RESEARCH FOUNDATION

A-16, Tons Colony, Dakhpathar, District Dehradun, 248125 (Uttrakhand), INDIA
e-mail : ybsrfoundation@gmail.com

Ref./YBSRF/1978/2017-18/58 Date: 05-02-2018

To,

Dr. Mukti Bhatnagar

Department Of Medicine,

Subharti Medical College

Dear Dr. Bhatnagar,

After carefully going through the project "**To Study Levels Of Fibrinogen , D-Dimer And 1L-6 Levels In Patients Of Covid 19 ; And Their Co-Relation In Mild, Moderate And Severe Cases Of Covid 19**" submitted by you, we are glad to inform you that we are willing to fund the project up to the tune of **INR 2700/-** in the form of consumables. Kindly submit the findings of the project after the completion.

All the best.

Regards,

Younker Buddhist Society And Research Foundation Secretary Dehradun

Dr Chandrakitti
Secretary

ABUSHIS GRAMIN SEWA SANSTHAN

IBEI Campus, Meerut Road, Hapur-245101PanchsheelNagar(UP) India
Tel.: +91- 9456137909, E-mail: agss1995@rediffmail.com

Ref.AGSS1995/2017:18/13....

Date: 12-01-2018

To,

Dr. ARUNIM SWARUP

Department of Orthopaedics

Subharti Medical College

Dear Dr. SWARUP

We are delighted to inform you that we are willing to fund the project up to **INR 3800/-** in consumables after thoroughly evaluating your project "**Clinico-radiological evaluation of results of biplane double supported screw fixation(bdsf) in femoral neck fractures.**" Once the project is finished, please submit the findings.

Thank you

Regards

For Abushis Gramin Sewa Sansthan

President/Secretary

ABUSHIS GRAMIN SEWA SANSTHAN

IBEI Campus, Meerut Road, Hapur-245101PanchsheelNagar(UP) India
Tel.: +91- 9456137909, E-mail: agss1995@rediffmail.com

Ref AGSS1995/2017-18/12 Date: 08-01-2018

To,

DR. VANDANA SHRIVASTAVA

Department of Microbiology

Subharti Medical College

Dear Dr Shrivastava

We are delighted to inform you that we are willing to fund the project up to **INR 3700/-** in consumables after thoroughly evaluating your project "**To study of the inducible clindamycin resistance in clinical isolate of staphylococcus aureus in tertiare hospital.**" Once the project is finished, please submit the findings.

Thank you

Regards

For Abushis Gramin Sewa Sansthan

President/Secretary

ABUSHIS GRAMIN SEWA SANSTHAN

IBEI Campus, Meerut Road, Hapur-245101PanchsheelNagar(UP) India
Tel.: +91- 9456137909, E-mail: agss1995@rediffmail.com

Ref.AGSS1995/2017:18/14....

Date: 15-01-2018

To,

Dr. T. R. SIROHI

Department of Medicine

Subharti Medical College

Dear Dr. T. R. SIROHI,

We are delighted to inform you that we are willing to fund the project up to **INR 3500/-** in consumables after thoroughly evaluating your project "**Serum prolactin levels in patients with seizure disorder.**" Once the project is finished, please submit the findings.

Thank you

Regards

For Abushis Gramin Sewa Sansthan

President/Secretary

ABUSHIS GRAMIN SEWA SANSTHAN

IBEI Campus, Meerut Road, Hapur-245101Panchsheel Nagar(UP) India
Tel.: +91- 9456137909, E-mail: agss1995@rediffmail.com

Ref.AGSS1995/2017-18/15....

Date: 19-01-2018

To,

Dr. V. K. Malik

Department of Ophthalmology

Subharti Medical College

Dear Dr. Malik

We are delighted to inform you that we are willing to fund the project up to **INR 3200/-** in consumables after thoroughly evaluating your project "**Study of correlation between serum uric acid and diabetic retinopathy.**" Once the project is finished, please submit the findings.

Thank you

Regards

For Abushis Gramin Sewa Sansthan

President/Secretary

ABUSHIS GRAMIN SEWA SANSTHAN

IBEI Campus, Meerut Road, Hapur-245101PanchsheelNagar(UP) India
Tel.: +91- 9456137909, E-mail: agss1995@rediffmail.com

Ref.AGSS1995/2017:18/16....

Date: 22-01-2018

To,

Dr. Nishant Wadhera

Department of Medicine

Subharti Medical College

Dear Dr. Nishant Wadhera

We are delighted to inform you that we are willing to fund the project up to **INR 3000/-** in consumables after thoroughly evaluating your project "**To study lipid profile in patients of rheumatoid arthritisand it's correlation with inflammatory markers.**" Once the project is finished, please submit the findings.

Thank you

Regards

For Abushis Gramin Sewa Sansthan

President/Secretary

VIKRAMSHILA SHODH SANSTHAN

Ref./VSS/50-10-11/17-18/24 Date: 19-02-2018

To,

Dr. Abhishek Gupta

Department of Medicine

Subharti Medical College

Dear Dr Gupta,

We are pleased to notify you that, after carefully reviewing your project "**Alteration of cardiovascular autonomic activity in type 2 diabetes mellitus**," we are willing to fund the project up to the tune of **INR 3000**/- in the form of consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Gyalbo

Mr. Tsering Gyalbo

CHAIRMAN / EXECUTIVE SECRETARY
VIKRAMSHILA SHODH SANSTHAN

Buddhist Colony, Dakpathar Road, Vikas Nagar, Dehradun (Uttarakhand) Pincode- 248198
Email- vikramshila4072@gmail.com Cell. No. 9568986411

VIKRAMSHILA SHODH SANSTHAN

Ref./VSS/50-10-11/17-18/20 Date: 05-02-2018

To,

Dr. Manoranjan Bansal

Department of Anaesthesiology & Critical care

Subharti Medical College

Dear Dr Bansal,

We are pleased to notify you that, after carefully reviewing your project "**A comparative clinical study of effect of intravenous dexmedetomidine vs intravenous clonidine on subarachnoid block with 0.5% hyperbaric bupivacaine in patients undergoing infraumblical surgeries**," we are willing to fund the project up to the tune of **INR 3000**/- in the form of consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Gyalbo

CHAIRMAN / EXECUTIVE SECRETARY
VIKRAMSHILA SHODH SANSTHAN

Buddhist Colony, Dakpathar Road, Vikas Nagar, Dehradun (Uttarakhand) Pincode- 248198
Email- vikramshila4072@gmail.com Cell. No. 9568986411

VIKRAMSHILA SHODH SANSTHAN

Ref./VSS/50-10-11/17-18/21 Date: 08-02-2018

To,

Dr (Prof) SHASHANK MISHRA

Department of General Surgery

Subharti Medical College

Dear Dr Mishra,

We are pleased to notify you that, after carefully reviewing your project "**Role of laparoscopy in evaluation and management of hollow viscus perforation**," we are willing to fund the project up to the tune of **INR 2800/-** in the form of consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Gyalbo

Mr. Tsering Gyalbo

CHAIRMAN / EXECUTIVE SECRETARY
VIKRAMSHILA SHODH SANSTHAN

Buddhist Colony, Dakpathar Road, Vikas Nagar, Dehradun (Uttarakhand) Pincode- 248198
Email- vikramshila4072@gmail.com Cell. No. 9568986411

VIKRAMSHILA SHODH SANSTHAN

Ref./VSS/50-10-11/17-18/22 Date: 12-02-2018

To,

Dr. MUKTA MITAL

Department of Radio-diagnosis & Imaging,

Subharti Medical College

Dear Dr Mital,

We are pleased to notify you that, after carefully reviewing your project "**Gestational age evaluation by measurement of placental thickness on ultrasonography**," we are willing to fund the project up to the tune of **INR 2800**/- in the form of consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Gyalbo

CHAIRMAN / EXECUTIVE SECRETARY
VIKRAMSHILA SHODH SANSTHAN

Buddhist Colony, Dakpathar Road, Vikas Nagar, Dehradun (Uttarakhand) Pincode- 248198
Email- vikramshila4072@gmail.com Cell. No. 9568986411

VIKRAMSHILA SHODH SANSTHAN

Ref./VSS/50-10-11/17-18/23 Date: 16-02-2018

To,

DR.(COL.) DAVENDRA SWARUP

Department of Pathology,

Subharti Medical College

Dear Dr Swarup,

We are pleased to notify you that, after carefully reviewing your project "**Haematological scoring system: an early predictor of neonatal sepsis,**" we are willing to fund the project up to the tune of **INR 2500/- in** the form of consumables.

Please report the project's findings once it has been completed.

All the best.

Regards

Mr. Tsering Gyalbo

CHAIRMAN / EXECUTIVE SECRETARY
VIKRAMSHILA SHODH SANSTHAN

Buddhist Colony, Dakpathar Road, Vikas Nagar, Dehradun (Uttarakhand) Pincode- 248198
Email- vikramshila4072@gmail.com Cell. No. 9568986411

M.: 7017661671

मुहिम प्रकाशन

123, काजीवाड़ा, हापुड़–245101 (उ.प्र.)

पत्रांक MP/2016-17/105 दिनांक 29-11-2017

To,

Er. Archita Bhatnagar and Shubhra Sharma,

Department of CSE,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Madam/Sir,

This is to inform you that, based on a comprehensive analysis of your project **"Multimodal biometric system using RF ID,"** we are able to provide you with supplemental stationeries and consumables worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for your time and attention.

For MUHIM PRAKASHAN

Prop

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2016-17/52 Dated 16-02-2018

To,

Ms. Vartika Tyagi

Department of ECE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Ms. Tyagi,

We are pleased to inform you that, after a comprehensive review of your project "**ENERGY TAPPING AND DETECTION**," we are willing to fund the project up to the tune of INR 1000/- in consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

(Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India)

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2016-17/53

Dated 16-02-2018

To,

Mr. Dharmendra Verma

Department of ECE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Mr. Verma,

We are pleased to inform you that, after a comprehensive review of your project **"CNG/LPG GAS DETECTION AND CONTROL SYSTEM USING MOBILE,"** we are willing to fund the project up to the tune of INR 1400/- in consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2016-17/54

Dated 16-02-2018

To,

Mr. Amit Kumar

Department of ECE.

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Mr. Kumar,

We are pleased to inform you that, after a comprehensive review of your project "**GSM BASED NOTICE BOARD,**" we are willing to fund the project up to the tune of INR 1700/- in consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

0521 9402813
0521 9402815

INDRAPRASTHA PRIVATE I.T.I.

(Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India)

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2016-17/55 Dated 16-02-2017

To,

Mr. Rajesh Parihar

Department of ECE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Mr. Parihar,

We are pleased to inform you that, after a comprehensive review of your project **"IOT BASED SMART LED STREET LIGHTING,"** we are willing to fund the project up to the tune of INR 3500/- in consumables. Please report the project's findings once it has been completed.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

अदीबा बुक्स

काली मस्जिद, हापुड़-245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/16 दिनांक 29-11-2017

To,

Er. Abhishek Tiwari,

Department of CE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Tiwari,

We are glad to announce you that, following an internal review of your project " **Investigating the Compressive Strength of Pet Bottles as Masonry,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

Prop.

अदीबा बुक्स

काली मस्जिद, हापुड़–245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/17 दिनांक 29-11-2017

To,

Er. Peer Fazil,

Department of CE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Fazil,

We are glad to announce you that, following an internal review of your project "**Comparative study of different method of curing,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2017-18/72

Dated 12-02-2018

To,

Mr. Vikas Sharma

Department of ECE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Mr. Sharma,

Following a thorough examination of your project **"AUTOMATIC STOPPING OF TRAIN WHEN RED LIGHT COMES,"** we are glad to inform you that we are willing to sponsor consumables up to INR 1200/-. Once the study is completed, please send the results.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

(Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India)

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2017-18/73 Dated 12-02-2018

To,

Mr. Supratim Saha

Department of ECE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Mr. Saha,

Following a thorough examination of your project "**HOME AUTOMATION USING ARDUINO**," we are glad to inform you that we are willing to sponsor consumables up to INR 2000/-. Once the study is completed, please send the results.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2017-18/74

Dated 12-02-2018

To,

Ms. Neha Verma

Department of ECE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Ms. Verma,

Following a thorough examination of your project "**IOT BASED SECUIRTY SYSTEM**," we are glad to inform you that we are willing to sponsor consumables up to INR 3000/-. Once the study is completed, please send the results.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

Website : www.indraprasthaprivateiti.com
e-mail : ipitihapur@gmail.com

09219402813
09219402815

INDRAPRASTHA PRIVATE I.T.I.

(Affiliated to NCVT, DGE&T, Ministry of Labour & Employment, Govt. of India)

Indraprastha Knowledge Park, Jarothi, Garh Road, HAPUR-245101 (U.P.)

Ref. No. IPITI/2017-18/75

Dated 12-02-2018

To,

Er. Ajay Kumar,

Department of EEE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Kumar,

Following a thorough examination of your project "**Modeling and Simulation of Half Bridge LLC Resonant Converter using Controllers**," we are glad to inform you that we are willing to sponsor consumables up to INR 1000/-. Once the study is completed, please send the results.

All the best.

Regards

Indraprastha Pvt. I.T.I. Hapur Secretary

अदीबा बुक्स

काली मस्जिद, हापुड़–245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/18 दिनांक 29-11-2017

To,

Er. Dhairya Narayan, and Prakhar Srivatava,

Department of EEE,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Sir,

We are glad to announce you that, following an internal review of your project "**Power quality enhancement of off-grid solar system by using ann,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

Prop.

अदीबा बुक्स

काली मस्जिद, हापुड़-245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/19 दिनांक 29-11-2017

To,

Er. Ravi Agarwal and Vimal Kumar,

Department of EEE,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Sir,

We are glad to announce you that, following an internal review of your project "**Closed Loop Speed Control of BLDC Motor using Microcontroller and LABVIEW Interface Monitoring,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

अदीबा बुक्स

काली मस्जिद, हापुड़–245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/20 दिनांक 29-11-2017

To,

Er. Harpreet Singh,

Department of ME,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Singh,

We are glad to announce you that, following an internal review of your project " **Design and fabrication of chainless bicycle,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

Prop.

अदीबा बुक्स

काली मस्जिद, हापुड़–245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/21 दिनांक 29-11-2017

To,

Er. Ajay Kumar Jena,

Department of ME,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Jena,

We are glad to announce you that, following an internal review of your project "**Hybrid e-rickshaw puller,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

Prop.

अदीबा बुक्स

काली मस्जिद, हापुड़-245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/22 दिनांक 29-11-2017

To,

Er. Harpreet Singh ,

Department of ME,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Singh,

We are glad to announce you that, following an internal review of your project "**Paddle Operated Grass Cutter to Save Electricity,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

Prop.

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़-245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Vishwas Mishra

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Mishra,

We are pleased to inform you that, following our internal analysis of your project "**Automatic vehicle braking system**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Sakshar Prakashan

Proprietor

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़–245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Supratim Saha

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Saha,

We are pleased to inform you that, following our internal analysis of your project "**Home automation using Arduino**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Sakshar Prakashan

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़–245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Ravi Agarwal

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Agarwal,

We are pleased to inform you that, following our internal analysis of your project "**DC moter speed control by android,**" we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Sakshar Prakashan

Director

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़–245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. P. K.Kaushal

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Kaushal,

We are pleased to inform you that, following our internal analysis of your project "**Smart helmet**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Saksher Prakashan

Proprietor

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़–245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. T. Ramachandran

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Ramachandranl,

We are pleased to inform you that, following our internal analysis of your project "**Wireless based device control**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Saksiar Prakashan

Proprietor

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़-245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Gajander

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Gajander,

We are pleased to inform you that, following our internal analysis of your project "**Paddle operated grass cutter to save electricity**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Saksher Prakashan

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़-245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Deepali Arora

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Arora,

We are pleased to inform you that, following our internal analysis of your project "**Fabrication of modified air cooler**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Sakshar Prakashan

Proprietor

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़–245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Guru Sewak Kesharwani

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Kesharwani,

We are pleased to inform you that, following our internal analysis of your project "**Portable solar power trolley bag,**" we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Saksher Prakashan

Proprietor

Mob.: 8791848615

नवसाक्षर प्रकाशन

1178, काजीवाड़ा, हापुड़-245101 (उ0प्र0)

Date: 29/12/2017

To,

Er. Abhishek Tiwari

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Er. Tiwari,

We are pleased to inform you that, following our internal analysis of your project "**Study behavior of self-healing concrete**," we are able to provide you with additional stationery and consumables valued up to INR 1000/-.

Once you've finished the study, please provide us a full report on your findings.

Regards, and I appreciate your deliberation.

For Nav Sakshar Prakashan

Proprietor

M.: 7017661671

मुहिम प्रकाशन

123, काजीवाड़ा, हापुड़–245101 (उ.प्र.)

पत्रांक MP/2017-18/105 दिनांक 29-11-2017

To,

Er. Abhishek Tiwari,

Department of CE,

Subharti Institute ofTechnology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Tiwari,

This is to inform you that, based on a comprehensive analysis of your project " **Sprinkler Irrigation,**" we are able to provide you with supplemental stationeries and consumables worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for your time and attention.

For MUHIM PRAKASHAN

Prop

M.: 7017661671

मुहिम प्रकाशन

123, काजीवाड़ा, हापुड़–245101 (उ.प्र.)

पत्रांक MP/2017-18/106 दिनांक 29-11-2017

To,

Er. Harpreet Singh,

Department of ME,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Singh,

This is to inform you that, based on a comprehensive analysis of your project "**Pedal Powered Hacksaw,**" we are able to provide you with supplemental stationeries and consumables worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for your time and attention.

For MUHIM PRAKASHAN

Prop

M.: 7017661671

मुहिम प्रकाशन

123, काजीवाड़ा, हापुड़–245101 (उ.प्र.)

पत्रांक MP/2017-18/107 दिनांक 29-11-2017

To,

Er. Ravi Agarwal

Department of EEE,

Subharti Institute of Technology & Engineering

Swami Vivekanand Subharti University, Meerut

Dear Er. Agarwal,

This is to inform you that, based on a comprehensive analysis of your project **"Fabrication of Automatic Power Factor Corrector,"** we are able to provide you with supplemental stationeries and consumables worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for your time and attention.

For MUHIM PRAKASHAN

Prop

Crazy Cub
ANIMATION STUDIO
Address: 6, Pocket 15, Sector-24, Rohini, Delhi, 110085

To : Nandlal Bose Subharti College of Fine Arts & Fashion

Respected Sir

At Crazy Cub we bring imaginations in to life. With use of 2D, 3D or live action tools, we bring ideas to screen. We are planning to upgrade further and to expand ourselves in graphic designing field for better opportunities. Hence, in this regard we would like to offer the students of Animation Dept. of Nandlal Bose Subharti College of Fine Arts and Fashion Design to come up with some innovative graphic templates..

Thanks & Regards

Kamal Pahuja

C.E.O

BDM

To: Nandlal Bose Subharti College of Fine Arts And Fashion Design

BDM is a leading Cricket bat and Kit sports wear manufacturer based in Meerut and we are planning to further expand into Fotball jersey and kit . In this regard i would like to offer and collaborate with Nandlal Bose Subharti College of Fine Arts and Fashion Design students for designing of our fotball kit and Jersey .

Thanks and Regards

Sujeet Sinhgal
BDM

CENTER OF SOCIAL AND POLITICAL STUDIES

Ref. No./CSPC/2017-18/01 Date: 05-07-2017

To,

Dr Nishma Singh

Subharti College of Home Science

Swami Vivekanand Subharti University, Meerut

Dear Dr Singh,

We are glad to inform you that, following a comprehensive evaluation of your proposal "**Role of skill education on personality development and psychological well being women,**" we are willing to support it with items worth up to INR 1000/-.

Please provide the findings once the study is completed.

All the best.

Regards

Zb-2 she Vikas Apartment-68, Patparganj, Delhi-92. E-mail: delhicsps@gmail.com

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

8

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/20

Date: 23-10-2017

To,
Dr. Sumit Raghav and Dr. Anshika Singh,
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

E-106

Dear Sir/Madam,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing CRAPE BANDAGE 6'' (worth INR 1200) received from K S CARE for your research project entitled " **Role of swiss ball exercises in reducing pain, disability and improving muscle endurance in patients with mechanical low back ache ".**
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Enticeway Tradelink Private Limited

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

9

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/16

Date: 23-10-2017

To,
Dr. Sumit Raghav and Dr. Anshika Singh,
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

E93

Dear Sir/Madam,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing ELASTIC SHOULDER IMMOLIZER (M)BDB (worth INR 2500) received from BDB for your research project entitled "**A study to compare the effectiveness of mulligan 'mwm' technique versus kaltenborn mobilization technique on pain and end range of motion in patients with adhesive capsulitis of shoulder joint: a randomized controlled trial**". Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Enticeway Tradelink Private Limited
For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

10

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/17

Date: 23-10-2017

To,
Dr. Sumit Raghav and Dr. Anshika Singh,
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

E-103

Dear Sir/Madam,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing SPINAL NEEDLE NO18 (worth INR 1000) received from ROMSONS for your research project entitled **"Short-term effect of lower limb neural stretch versus pelvic traction along with spinal extension exercises on pain and disability in patients with lower back pain with radiculopathy: a randomized clinical trial".**
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Enticeway Tradelink Private Limited
For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

11

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/19

Date: 23-10-2017

To,
Dr. Anshika Singh and Dr. Sumit Raghav,
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

E-105

Dear Sir/Madam,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing HARD CERVICAL COLLAR (L)BDB (worth INR 1200) received from B.D.B for your research project entitled "**A Comparative Study on the Effects of Two Different Positions of Intermittent Cervical Traction in Cervical Radiculopathy**".
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Private Limited

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/18

To,
Dr. Anshika Singh and Dr. Sanjai Kumar,
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Date: 23-10-2017

Dear Sir/Madam,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing SPINAL NEEDLE [BD] NO. 23 (worth INR 1000) received from B.D.[BECTON DICKINSON LTD for your research project entitled "**Short-term effect of lower limb neural stretch versus pelvic traction along with spinal extension exercises on pain and disability in patients with lower back pain with radiculopathy: a randomized clinical trial**". Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 43

To,

Date: 15/12/2017

Dr. Anshika Singh and Dr. Sumit Raghav
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir/Ma'am,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing DIGITAL THERMOMETER PACK 1 (worth INR 2000) received from INSTRUMENTS for your research project entitled **"A study to compare the effect of cranial-based releae technique versur conventional programme on pain and disability in patients with cervicogenic headache: a randomized clinical trail".**
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

For Enticeway Tradelink Private Limited

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 39

Date: 11/12/2017

To,
Dr. Ashutosh and Dr. Pradeep
Subharti Dental College
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Enticeway Tradelink Pvt. Ltd. are providing NEEDLE 16NO [1.5INC] * 200 (worth INR 600) received from ROMSONS for your research project entitled **"Comparative evaluation of skeletalan dental changes by using power scope and advance sync. Molar to molar class II (MOMC) in class II malocclusion".** Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Enticeway Tradelink Private Limited
For Enticeway Tradelink Pvt. Ltd.

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 47

Date: 15/12/2017

To,
Dr. Danish Nouman
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Dr. Nouman,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing HARD CERVICAL COLLAR (L) BDB (worth INR 1000) received from BDB for your research project entitled **"A study of the compare the effect of intermittent mechanical traction and manual traction to reduce pain and radioculopathy on cervical spondylsis"**. Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Private Limited
For Entice Way Tradelink Pvt. Ltd.
Authorised Signatory

Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 47

Date: 15/12/2017

To,
Dr. Danish Nouman
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Dr. Nouman,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing HARD CERVICAL COLLAR (L) BDB (worth INR 1000) received from BDB for your research project entitled **"A study of the compare the effect of intermittent mechanical traction and manual traction to reduce pain and radioculopathy on cervical spondylsis".** Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Private Limited
For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P. 2500004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/23

Date: 6/12/2017

To,
Dr. Faizi Muzzafar and Mr. Prasanjit Paul
Kharvel Subharti College of pharmacy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing GLOVES 7 NO NULIFE*10 (worth INR 520) received from HEALTHIUM MEDTECH PVT. LTD for your research project entitled "**Design Development evaluation of topical microemulsion**"
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

For Entice Way Tradelink Private Limited

Authorised Signatory

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P. 2500004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/24

Date: 6/12/2017

To,
Dr. Faizi Muzzafar
Kharvel Subharti College of pharmacy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Dr. Muzzafar,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing STERILE WATER 1000ML (worth INR 900) received from PRIYA AYURVEDIC PRODUCTS for your research project entitled "**Proposal of support for incubation leading to star-up**"
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P. 2500004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 26

Date: 6/12/2017

To,
Dr. Faizi Muzzafar
Kharvel Subharti College of pharmacy
Swami Vivekanand Subharti University
Meerut. Uttar Pradesh

Dear Dr. Muzzafar,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing STERILE WATER 1000ML (worth INR 900) received from PRIYA AYURVEDIC PRODUCTS for your research project entitled "**Design development and evaluation of topical antiseptic formulations"**
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P. 2500004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/25

Date: 6/12/2017

To,
Mr. Gaurav Updhyay and Mr. Manish Pathak
Kharvel Subharti College of pharmacy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing BACTERIAL VIRAL FILTER ADULT (worth INR 333) received from VENTUS for your research project entitled "**Antibacterial activity of phyllanthusamarus plant extract against resistant pathogenic bacterial strains**"
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

For Enticeway Tradelink Private Limited

Authorised Signatory

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 44

Date: 15/12/2017

To,
Dr. Kapil Rastogi and Dr. Gaurav PratapTyagi
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing HARD CERVICAL COLLAR (L)BDB (worth INR 2000) received from BDB for your research project entitled **"A study on the effect of transcutaneous electrical stimulation in patients with cervical brachialgia".**
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

ENTICE WAY TRADELINK PVT. LTD. Meerut

For Enticeway Tradelink Private Limited

Authorised Signatory

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 44

Date: 15/12/2017

To,
Dr. Kapil Rastogi and Dr. Gaurav PratapTyagi
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing HARD CERVICAL COLLAR (L)BDB (worth INR 2000) received from BDB for your research project entitled **"A study on the effect of transcutaneous electrical stimulation in patients with cervical brachialgia".**
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

ENTICE WAY TRADELINK PVT. LTD. Meerut

For Enticeway Tradelink Private Limited

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/50

Date: 15/12/2017

To,
Dr. Mukesh Kumar
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Dr. Kumar,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing CRAPE BANDAGE 6'' (worth INR 1500) received from K S CARE for your research project entitled " **Effectiveness of PNF stretching of hemstrings muscule** ".
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Enticeway Tradelink Private Limited

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Meerut

Authorised Signatory

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P. 2500004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/07

Date: 19-09-2017

To,
Dr. Shefali Pushp and Dr. Sumit Raghav,
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Sir/Madam,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing DIGITAL THERMOMETER PACK 1 (worth INR 1000) received from INSTRUMENTS for your research project entitled "**Lasting effect of single seesion muscle energy technique to gain hamstring flexibility in asymptomatic normal healthy females: quasi experimental study** ".
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Enticeway Tradelink Private Limited

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

ENTICE WAY TRADELINK PVT. LTD. Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 49

To,
Dr. Sumit Raghav and Dr . Anshika Singh
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Date: 15/12/2017

Dear Sir/Ma'am,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing KNEE BRACE BDB (S) (worth INR 2000) received from BDB for your research project entitled **"Role of functional faradism in improving qaulity of life in patients with knee osteoarthritis"**.
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Private Limited
For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/45

Date: 15/12/2017

To,
Dr. Surandar kumar
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Dr. Kumar,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing DIGITAL THERMOMETER PACK 1 (worth INR 2000) received from INSTRUMENTS for your research project entitled **"Effect of four week's supervised phase-11 cardiac rehabilitation on heart rate recovery after sub maximal exercise testing in the patient with CABG ".**

Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

Meerut

CIN No.:U74900UP2009PTC038556
Reg.No: 038556

ENTICE WAY TRADELINK PVT. LTD.

A-5, Samrat Place, Garh Road, Meerut – U.P .250004
Phone No.: 7902134534 E-mail: ewtcpl123@gmail.com

Eway/Res/2017-18/ 48

Date: 15/12/2017

To,
Dr. Uzma Khan
Subharti College of Physiotherapy
Swami Vivekanand Subharti University
Meerut, Uttar Pradesh

Dear Dr. Khan,

As swami Vivekanand Subharti University is well known for being one of the most actively involved in several research projects. Hence, on your request, we Entice Way Tradelink Pvt. Ltd. are providing LUMBAR SACRO BELT (XL) BDB (worth INR 1000) received from BDB for your research project entitled **"Efficacy of swiss ball exercise vs. floor excersies in mechanical low back pain- a comparative study"**.
Your report will be shared with the manufacturer.

Thanking you

Sincerely

For Entice Way Tradelink Private Limited
For Entice Way Tradelink Pvt. Ltd.

Authorised Signatory

Authorised Signatory

Gyan Amrit Oral Health And Cancer Research Foundation

Ref. No.: 010/08/2017 Date: 25/08/2017

To,

Dr. Sachin Gupta

Subharti Dental College & Hospital

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Gupta,

We are pleased to notify you that, following a thorough review of your concept " **Effect of different bonding protocols on the bond strength of self adhering composite dentin: An in vitro study**," we are willing to grant financial assistance in the form of items up to INR 1000/-.

Once the project is finished, please submit your findings.

All the best.

Regards

Dr Ankit Goel

For GYAN AMRIT ORAL HEALTH AND CANCER RESEARCH FOUNDATION

President Secretary-cum-Treasurer

Dr. Goel's Dental & Maxillofacial Diagnostics
23-28, Ground Floor, City Plaza, Hapur. Ph: 0122-2317172, 09897675797
Visit us at www.drgoelsdiagnostics.com E-mail : drankitgoel21@gmail.com

Gyan Amrit Oral Health And Cancer Research Foundation

Ref. No.: 018/08/2017 Date: 27/08/2017

To,

Dr. Sachin Gupta

Subharti Dental College & Hospital

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Gupta,

We are pleased to notify you that, following a thorough review of your concept " **Effect of antioxidant on bond strength of resin cement to dentin**," we are willing to grant financial assistance in the form of items up to INR 1000/-.

Once the project is finished, please submit your findings.

All the best.

Regards

Dr Ankit Goel

For GYAN AMRIT ORAL HEALTH AND CANCER RESEARCH FOUNDATION

President Secretary / Treasurer

Dr. Goel's Dental & Maxillofacial Diagnostics
23-26, Ground Floor, City Plaza, Meerut. Ph: 0121-2317172, 09897675707
Visit us at : www.drgoelsdiant.com E-mail : drankitgoel21@gmail.com

Gyan Amrit Oral Health And Cancer Research Foundation

Ref. No.: 032/09/2017 Date: 27/09/2017

To,

Dr Shikha Jaiswal

Subharti Dental College & Hospital

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Jaiswal,

We are pleased to notify you that, following a thorough review of your concept **"Comparative evaluation of accuracy of newer generation apex locators in different clinical scenarios,"** we are willing to grant financial assistance in the form of items up to INR 1000/-.

Once the project is finished, please submit your findings.

All the best.

Regards

Dr Ankit Goel

For GYAN AMRIT ORAL HEALTH AND CANCER RESEARCH FOUNDATION

President Treasurer

Dr. Goel's Dental & Maxillofacial Diagnostics
25-26, Ground Floor, City Plaza, Hapur. Ph: 0122-2317172, 09897075707
Visit us at : www.drgoelsdmd.com E-mail : drankitgoel21@gmail.com

Gyan Amrit Oral Health And Cancer Research Foundation

Ref. No.: 021/09/2017 Date: 01/09/2017

To,

Dr Vineeta Nikhil

Subharti Dental College & Hospital

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Nikhil,

We are pleased to notify you that, following a thorough review of your concept " **Effect of eugenol on bond strength and marginal sealing ability of different composites: An in vitro study**," we are willing to grant financial assistance in the form of items up to INR 1000/-.

Once the project is finished, please submit your findings.

All the best.

Regards

Dr Ankit Goel

For GYAN AMRIT ORAL HEALTH AND CANCER RESEARCH FOUNDATION

President Secretary Treasurer

Dr. Goel's Dental & Maxillofacial Diagnostics
25-26, Ground Floor, City Plaza, Hapur. Ph: 0122-2317172, 09897675707
Visit us at www.drgoeladmit.com E-mail : drankitgoel21@gmail.com

ज्ञान विज्ञान संस्थान
किला कोना, हापुड़-245101 (उ0प्र0)
Mob.: +91-8791161658

Date: 05-02-2018

To,

Dr. Jitendra Kumar

Department of Mathematics,

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University, Meerut, Uttar Pradesh

Dear Dr. Kumar,

Based on the internal examination of your project "**Profit optimization of Baghpat District co-operative Bank as Linear Programming Problem,**" we are pleased to inform you that we are able to provide you with additional stationeries and consumables worth up to INR 1000/-. Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for taking the time to consider this.

For Gyan Vigyan Sansthan

Prop.

JYOTI PUNJ MAHILA AVAM GRAM VIKAS SANSTHAN

Date: 20-09-2017

To,

Dr. Suchitra Tyagi,

Department of Chemistry

Keral Verma Subharti College of Science,

Swami Vivekanand Subharti University, Meerut

Dear Dr. Tyagi,

Women's empowerment is our goal, and we assist women in achieving that goal. We've conducted a thorough evaluation of your project "Characterization of partially purified α-amylase extracted from mung bean seeds," and we're pleased to inform you that, based on our findings, we'd want to aid you with your venture by providing free consumables worth up to INR 1000. Please send us an in-depth explanation of your findings as soon as the assignment is finished.

Thank you

Secretary

Dr. Nityanand Saini

Date: 20-09-2017

To,

Dr. Shashi Bala,

Department of Chemistry

Keral Verma Subharti College of Science,

Swami Vivekanand Subharti University, Meerut

Dear Dr. Bala,

Women's empowerment is our goal, and we assist women in achieving that goal. We've conducted a thorough evaluation of your project " Vermicomposting: An environmental friendly process treating waste and manure," and we're pleased to inform you that, based on our findings, we'd want to aid you with your venture by providing free consumables worth up to INR 1000. Please send us an in-depth explanation of your findings as soon as the assignment is finished.

Thank you

Secretary

Dr. Nityanand Saini

कृष्णा इनोवेशन्स प्रा. लि.
KRISHNA INNOVATIONS PVT. LTD.
Website: www.kipldindia.com
AGRICULTURE · HORTICULTURE · FORESTRY PRODUCTS

229

Date: 02/04/2018

To,

Dr. Dheerpal Singh

Department of Zoology

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Singh,

We are excited to share you that, begins with a thorough review of your project **"Assessment of water quality and fish diversity in upper ganges canal near Meerut city,"** we are able to assist you by supplying complementary pharmaceuticals, consumables, and chemicals valued up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Thank you for your time and consideration, and best regards.

Authorised Signatory

JYOTI PUNJ MAHILA AVAM GRAM VIKAS SANSTHAN

Date: 30-11-2017

To,

Dr. Razia Sultana,

Department of Zoology

Keral Verma Subharti College of Science,

Swami Vivekanand Subharti University, Meerut

Dear Dr. Sultana,

Women's empowerment is our goal, and we assist women in achieving that goal. We've conducted a thorough evaluation of your project "Nematode diversity of crop fields in Meerut district," and we're pleased to inform you that, based on our findings, we'd want to aid you with your venture by providing free consumables worth up to INR 1000. Please send us an in-depth explanation of your findings as soon as the assignment is finished.

Thank you

Secretary

Dr. Nityanand Saini

9837664159 Village Tiyala, Post Assoda, District Ghaziabad

144

K S Associates

(Business & Management Consultancy & Contracting Services)

BH-110, Phase-I, Pallavpuram, Meerut – 250110, Uttar Pradesh

GST NO. – 09BYTPS5446L2ZA

Date: 15/09/2017

To,

Dr. Anju Rani

E-158

Department of Botany

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Rani,

Following a comprehensive analysis of your project **"Effect of bacterial culture against causal agent of late light of potato,"** we are glad to inform you that we are able to assist you by providing complementary medications, consumables, and chemicals worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Thank you for your attention and time, and best wishes.

कमलेश शर्मा

Authorized Signatory

K.S. ASSOCIATES MEERUT

K S Associates
(Business & Management Consultancy & Contracting Services)
301-110, Phase-I, Pallavpuram, Meerut – 250110, Uttar Pradesh
GST NO. – 09BYTPS5446L2ZA

Date: 09/09/2017

To,

Dr. Permod Kumar

E-135

Department of Botany

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University

Meerut, Uttar Pradesh

Dear Dr. Kumar,

Following a comprehensive analysis of your project **"Characterization of Biosurfactant Producing Bacteria from Oil Contaminated Water,"** we are glad to inform you that we are able to assist you by providing complementary medications, consumables, and chemicals worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Thank you for your attention and time, and best wishes.

Authorized Signatory

K.S. ASSOCIATES MEERUT

अदीबा बुक्स

खाली मस्जिद, हापुड़-245101 (उ.प्र.), मो0 7983002274

पत्रांक AB/2017-18/07 दिनांक 17-11-2017

To,

Dr. Shasiraj Teotia

Department of Computer Application,

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University, Meerut, Uttar Pradesh

Dear Mr. Sirohi,

We are glad to announce you that, following an internal review of your project " **Task-Scheduling Implementation for Secure Wireless Networks Multikey Encryption Scheme & Network Protocol,**" we are able to provide you with additional stationeries and consumables valued at up to INR 1000/-.

Please provide us with a detailed report on your results once the project is completed.

Regards, and I appreciate your time and consideration.

For Adeeba Books

ज्ञान विज्ञान संस्थान
किला कोना, हापुड़-245 101 (उ0प्र0)
Mob.: +91-8791161658

Date: 20-01-2018

To,

Dr. Vikas Kumar

Department of Mathematics,

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University, Meerut, Uttar Pradesh

Dear Dr. Kumar,

Based on the internal examination of your project "**Profit Analysis and Modelling of a Power Plant with Boolean Function Algorithm,**" we are pleased to inform you that we are able to provide you with additional stationeries and consumables worth up to INR 1000/-.

Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for taking the time to consider this.

For Gyan Vigyan Sansthan

Prop.

ज्ञान विज्ञान संस्थान
किला कोना, हापुड़-245101 (उ0प्र0)
Mob.: +91-8791161658

Date: 05-02-2018

To,

Dr. Jitendra Kumar

Department of Mathematics,

Keral Verma Subharti College of Science

Swami Vivekanand Subharti University, Meerut, Uttar Pradesh

Dear Dr. Kumar,

Based on the internal examination of your project "**Profit optimization of Baghpat District co-operative Bank as Linear Programming Problem,**" we are pleased to inform you that we are able to provide you with additional stationeries and consumables worth up to INR 1000/-. Once the project is completed, please give us with a full report on your findings.

Regards, and thank you for taking the time to consider this.

For Gyan Vigyan Sansthan

Prop.

JYOTI PUNJ MAHILA AVAM GRAM VIKAS SANSTHAN

Date: 20-09-2017

To,

Dr. Suchitra Tyagi,

Department of Chemistry

Keral Verma Subharti College of Science,

Swami Vivekanand Subharti University, Meerut

Dear Dr. Tyagi,

Women's empowerment is our goal, and we assist women in achieving that goal. We've conducted a thorough evaluation of your project "Characterization of partially purified α-amylase extracted from mung bean seeds," and we're pleased to inform you that, based on our findings, we'd want to aid you with your venture by providing free consumables worth up to INR 1000. Please send us an in-depth explanation of your findings as soon as the assignment is finished.

Thank you

Secretary

Dr. Nityanand Saini

9837664159 Village Tiyala, Post Assoda, District Ghaziabad

Date: 20-09-2017

To,

Dr. Shashi Bala,

Department of Chemistry

Keral Verma Subharti College of Science,

Swami Vivekanand Subharti University, Meerut

Dear Dr. Bala,

Women's empowerment is our goal, and we assist women in achieving that goal. We've conducted a thorough evaluation of your project " Vermicomposting: An environmental friendly process treating waste and manure," and we're pleased to inform you that, based on our findings, we'd want to aid you with your venture by providing free consumables worth up to INR 1000. Please send us an in-depth explanation of your findings as soon as the assignment is finished.

Thank you

Secretary

Dr. Nityanand Saini

JYOTI PUNJ MAHILA AVAM GRAM VIKAS SANSTHAN

Date: 20-11-2017

To,

Dr. Ankita Agarwal,

Department of Chemistry

Keral Verma Subharti College of Science,

Swami Vivekanand Subharti University, Meerut

Dear Dr. Agarwal,

Women's empowerment is our goal, and we assist women in achieving that goal. We've conducted a thorough evaluation of your project "Study on bright red carotenoid extraction, a natural antioxidant from tomato," and we're pleased to inform you that, based on our findings, we'd want to aid you with your venture by providing free consumables worth up to INR 1000. Please send us an in-depth explanation of your findings as soon as the assignment is finished.

Thank you

Secretary

Dr. Nityanand Saini

9837664159 Village Tiyala, Post Assoda, District Ghaziabad

Jai Hind!!

Swami Vivekanand Subharti University, Meerut
(Established under U.P. Govt. Act no. 29 of 2008 and approved under section 2(f) of UGC Act 1956)